

**ACPE Accredited Provider**


**#0122**

**Annual Pharmacy CE Summary Report  
CE Activities of 2025**

# Report Contents

|   |    |
|---|----|
| Premier CE Program Participation .....                            | 3  |
| Summary of CE Hours Provided in 2025 .....                        | 4  |
| 2025 CE Participation Maps.....                                   | 5  |
| 2025 Evaluation Scoring Reports                                   |    |
| CE Teleconference Evaluations Report – Pharmacists .....          | 8  |
| CE Teleconference Evaluations Report – Pharmacy Technicians ..... | 9  |
| Antimicrobial Stewardship Forum Evaluations Reports.....          | 10 |
| Pharmacy Practice Forum Evaluations Reports .....                 | 11 |
| Home-Study CE Evaluations Report – Pharmacists .....              | 12 |
| Home-Study CE Evaluations Report – Pharmacy Technicians .....     | 13 |
| Breakthroughs CE Evaluations Report .....                         | 14 |
| Atlantic Health Evaluations Report .....                          | 15 |
| Other Live CE Evaluations Reports .....                           | 16 |
| 2025 CE Comments Reports  |    |
| CE Teleconference Comments Report - Pharmacists.....              | 19 |
| CE Teleconference Comments Report – Pharmacy Technicians.....     | 20 |
| Pharmacy Practice Forum Comments Reports.....                     | 21 |
| Antimicrobial Stewardship Forum Comments Reports.....             | 22 |
| Home-Study CE Comments Report - Pharmacists.....                  | 23 |
| Home-Study CE Comments Report – Pharmacy Technicians.....         | 25 |
| Breakthroughs CE Comments Report.....                             | 27 |
| Atlantic Health CE Comments Reports .....                         | 28 |
| Other Live CE Comments Reports .....                              | 29 |
| 2025 Overall CE Activity Ratings .....                            | 30 |

# Premier CE Program Participation



**Averages for 2025 CE activities (numbers are averages per CE activity based on annual registration and CE completion):**

- **Monthly CE Webinars: 669 registrants; 520 completed CE requirements**
- **Pharmacy Practice Forum: 670 registrants; 513 completed CE requirements**
- **Antimicrobial Stewardship Forum: 702 registrants; 529 completed CE requirements**


**Premier Member Meeting live CE totals in Dec 2025 (2 activities): 75 registrants; 56 completed CE requirements**

**Home-study CEs: 30 activities offered; average of 342 registrants each; average of 239 CE credit recipients each**


# Summary of CE Hours Provided in 2025

|   |
|---|
| Total Number of Live CE Activities Offered                      |
| 48  |
| Total Hours of Live CE Offered                                  |
| 48  |
| Total Number of Home-Study CE Activities Offered                |
| 37  |
| Hours of Home-study CE Offered                                  |
| 37  |
| Hours of CE Offered to Pharmacists (Live + Home-study)          |
| 85  |
| Hours of CE Offered to Pharmacy Technicians (Live + Home-study) |
| 85  |
| Active Learning Strategies Used in CE Activities                |
| Polling questions; case discussions; Q&A with speaker           |


## 2025 CE Webinar Registrants by State



### 2025 Antimicrobial Stewardship Forum Registrants by State



# 2025 Pharmacy Practice Forum Registrants by State



Premier, Inc.  
CE Teleconference Evaluations Report - Pharmacists  
2025

| Date and Working Program Title   | Speaker Name, e-mail address   | Credit Hrs | Total # of Registrants | Total # of CE Recipients | # of Pharmacists Receiving CE | Objectives were met | Activity met educational needs | Quality of faculty was satisfactory | Educational materials were useful | Teaching methods were effective | Learning assessment activities were appropriate | Actively participated in activity | Activity did not promote product or company | Overall Activity Rating | Specialty Areas     | Focus Areas (Outcomes, Safety, Best Practices) |
|--|--|------------|------------------------|--------------------------|-------------------------------|---------------------|--------------------------------|-------------------------------------|-----------------------------------|---------------------------------|---|-----------------------------------|---|-------------------------|---------------------|--|
| <b>January 23, 2025:</b> 340B Program – Looking Forward to 2025 After Another Tumultuous Year  | Jason B. Reddish;<br>Jason.Reddish@PowersLaw.com                                     | 1.0        | 845                    | 622                      | 526                           | 4.43                | 4.4                            | 4.44                                | 4.39                              | 4.39                            | 4.39  | 4.39                              | 4.43  | 4.41                    | Pharmacy Law        | Best Practices                                 |
| <b>February 25, 2025:</b> Clean Data and Polished Compliance: Leveraging AI Diversion Software to Optimize Alerts and Improve Controlled Substance Processes | Bethanie Gamble, PharmD;<br>Bethanie.Gamble@prismahealth.org                         | 1.0        | 689                    | 526                      | 447                           | 4.38                | 4.37                           | 4.37                                | 4.37                              | 4.37                            | 4.37  | 4.37                              | 4.4   | 4.38                    | Biotechnology       | Best Practices                                 |
| <b>March 27, 2025:</b> Don't Get Lost in the Alphabet Soup: Overview of Emerging Cancer Immune Therapies   | Genevieve Kumapley, PharmD, BCOP;<br>gkumapley@holyname.org                          | 1.0        | 714                    | 542                      | 468                           | 4.41                | 4.4                            | 4.43                                | 4.41                              | 4.39                            | 4.4   | 4.39                              | 4.43  | 4.41                    | Oncology            | Best Practices                                 |
| <b>April 23, 2025:</b> Health Equity in Practice: Addressing Bias and Social Drivers for Better Patient Outcomes   | Sally A. Arif, PharmD, BCCP;<br>sarif@midwestern.edu                                 | 1.0        | 697                    | 520                      | 441                           | 4.4                 | 4.36                           | 4.4                                 | 4.38                              | 4.39                            | 4.39  | 4.47                              | 4.4   | 4.40                    | Diversity           | Best Practices                                 |
| <b>May 29, 2025:</b> How It's Made: 503B Product Ingredients and Sterilization Methods   | Kevin N. Hansen, PharmD, MS, BCSCP;<br>kevin_hansen@premierinc.com                   | 1.0        | 753                    | 557                      | 483                           | 4.47                | 4.46                           | 4.48                                | 4.47                              | 4.47                            | 4.47  | 4.44                              | 4.48  | 4.47                    | Compounding         | Best Practices                                 |
| <b>June 17, 2025:</b> Incorporating Anti-Amyloid-β (Aβ) Monoclonal Antibody Therapies into Alzheimer's Disease Management                                    | Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP;<br>marketa.marvanova@pacificu.edu | 1.0        | 686                    | 517                      | 429                           | 4.44                | 4.43                           | 4.45                                | 4.44                              | 4.43                            | 4.44  | 4.41                              | 4.45  | 4.44                    | Alzheimer's Disease | Best Practices                                 |
| <b>July 23, 2025:</b> Specialty, Oncology, and ID Drugs: What is in the Pipeline? - The 2025 Update  | Liya Davydov, PharmD, BCPS, BCGP;<br>Liya_Davydov@premierinc.com                     | 1.0        | 474                    | 361                      | 296                           | 4.37                | 4.36                           | 4.35                                | 4.37                              | 4.34                            | 4.36  | 4.31                              | 4.4   | 4.36                    | Oncology            | Best Practices                                 |
| <b>August 13, 2025:</b> Biosimilars -The 2025 Update   | Liya Davydov, PharmD, BCPS, BCGP;<br>Liya_Davydov@premierinc.com                     | 1.0        | 698                    | 664                      | 584                           | 4.39                | 4.35                           | 4.39                                | 4.37                              | 4.34                            | 4.36  | 4.38                              | 4.42  | 4.38                    | Biosimilars         | Best Practices                                 |
| <b>September 18, 2025:</b> Leading with Intelligence: Embracing AI to Advance Pharmacy   | Rebecca A. Taylor, PharmD, MBA, BCPS, FASHP; taylorra4@upmc.edu                      | 1.0        | 641                    | 503                      | 426                           | 4.36                | 4.34                           | 4.34                                | 4.33                              | 4.34                            | 4.35  | 4.33                              | 4.36  | 4.34                    | AI + technologies   | Best Practices                                 |
| <b>October 23, 2025:</b> Stopping the Bleed in 2025: An Anticoagulation Reversal and Hemostasis Update   | Michael Gulseth, PharmD, BCPS, FMSHP, FASHP; michael.gulseth@sanfordhealth.org       | 1.0        | 662                    | 508                      | 440                           | 4.42                | 4.42                           | 4.41                                | 4.41                              | 4.41                            | 4.41  | 4.39                              | 4.43  | 4.41                    | Anticoagulation     | Best Practices                                 |
| <b>November 19, 2025:</b> From Guidelines to Bedside: Evolving HIV Care in Hospitalized Patients   | Shannon Balcombe, PharmD, BCPS, AAHIVP; sbalcombe@health.ucsd.edu                    | 1.0        | 621                    | 471                      | 401                           | 4.45                | 4.45                           | 4.45                                | 4.46                              | 4.45                            | 4.44  | 4.44                              | 4.47  | 4.45                    | HIV/AIDS            | Best Practices                                 |
| <b>December 17, 2025:</b> Human Trafficking from a Pharmacy Perspective (Working title)  | Anne Haring, PharmD;<br>Anne_Haring@pba.edu; annieferri@yahoo.com                    | 1.0        | 544                    | 448                      | 380                           | 4.45                | 4.44                           | 4.44                                | 4.43                              | 4.45                            | 4.45  | 4.43                              | 4.47  | 4.45                    | Administration      | Best Practices                                 |
|  | 4.46   |            |                        |                          |                               |                     |                                |                                     |                                   |                                 |   |                                   |   |                         |                     |  |

Premier, Inc.  
CE Teleconference Evaluations Report - Pharmacy Technicians  
2025

| Date and Working Program Title   | Speaker Name, e-mail address  | Credit Hrs | Total # of Registrants | Total # of CE Recipients | # of Pharmacy Technicians Receiving CE | Objectives were met | Activity met educational needs | Quality of faculty was satisfactory | Educational materials were useful | Teaching methods were effective | Learning assessment activities were appropriate | Actively participated in activity | Activity did not promote product or company | Overall Activity Rating | Specialty Areas     | Focus Areas (Outcomes, Safety, Best Practices) |  |
|--|---|------------|------------------------|--------------------------|--|---------------------|--------------------------------|-------------------------------------|-----------------------------------|---------------------------------|---|-----------------------------------|---|-------------------------|---------------------|--|--|
| <b>January 23, 2025:</b> 340B Program – Looking Forward to 2025 After Another Tumultuous Year  | Jason B. Reddish; Jason.Reddish@PowersLaw.com                                     | 1.0        | 845                    | 622                      | 96                                     | 4.39                | 4.36                           | 4.4                                 | 4.35                              | 4.38                            | 4.37  | 4.31                              | 4.36  | 4.37                    | Pharmacy Law        | Best Practices                                 |  |
| <b>February 25, 2025:</b> Clean Data and Polished Compliance: Leveraging AI Diversion Software to Optimize Alerts and Improve Controlled Substance Processes | Bethanie Gamble, PharmD; Bethanie.Gamble@prismahealth.org                         | 1.0        | 689                    | 526                      | 79                                     | 4.46                | 4.47                           | 4.46                                | 4.47                              | 4.44                            | 4.47  | 4.43                              | 4.43  | 4.45                    | Biotechnology       | Best Practices                                 |  |
| <b>March 27, 2025:</b> Don't Get Lost in the Alphabet Soup: Overview of Emerging Cancer Immune Therapies   | Genevieve Kumapley, PharmD, BCOP; gkumapley@holynome.org                          | 1.0        | 714                    | 542                      | 74                                     | 4.41                | 4.44                           | 4.42                                | 4.42                              | 4.41                            | 4.41  | 4.32                              | 4.44  | 4.41                    | Oncology            | Best Practices                                 |  |
| <b>April 23, 2025:</b> Health Equity in Practice: Addressing Bias and Social Drivers for Better Patient Outcomes   | Sally A. Arif, PharmD, BCCP; sarif@midwestern.edu                                 | 1.0        | 697                    | 520                      | 79                                     | 4.43                | 4.4                            | 4.42                                | 4.38                              | 4.38                            | 4.41  | 4.27                              | 4.43  | 4.39                    | Diversity           | Best Practices                                 |  |
| <b>May 29, 2025:</b> How It's Made: 503B Product Ingredients and Sterilization Methods   | Kevin N. Hansen, PharmD, MS, BCSCP; kevin_hansen@premierinc.com                   | 1.0        | 753                    | 557                      | 74                                     | 4.4                 | 4.43                           | 4.43                                | 4.44                              | 4.44                            | 4.4   | 4.27                              | 4.44  | 4.41                    | Compounding         | Best Practices                                 |  |
| <b>June 17, 2025:</b> Incorporating Anti-Amyloid-β (Aβ) Monoclonal Antibody Therapies into Alzheimer's Disease Management                                    | Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP; marketa.marvanova@pacificu.edu | 1.0        | 686                    | 517                      | 88                                     | 4.45                | 4.41                           | 4.45                                | 4.46                              | 4.44                            | 4.41  | 4.37                              | 4.43  | 4.43                    | Alzheimer's Disease | Best Practices                                 |  |
| <b>July 23, 2025:</b> Specialty, Oncology, and ID Drugs: What is in the Pipeline? - The 2025 Update  | Liya Davydov, PharmD, BCPS, BCGP; Liya_Davydov@premierinc.com                     | 1.0        | 474                    | 361                      | 65                                     | 4.36                | 4.35                           | 4.33                                | 4.36                              | 4.39                            | 4.36  | 4.3                               | 4.33  | 4.35                    | Oncology            | Best Practices                                 |  |
| <b>August 13, 2025:</b> Biosimilars -The 2025 Update   | Liya Davydov, PharmD, BCPS, BCGP; Liya_Davydov@premierinc.com                     | 1.0        | 698                    | 664                      | 80                                     | 4.44                | 4.41                           | 4.43                                | 4.46                              | 4.42                            | 4.44  | 4.38                              | 4.42  | 4.43                    | Biosimilars         | Best Practices                                 |  |
| <b>September 18, 2025:</b> Leading with Intelligence: Embracing AI to Advance Pharmacy   | Rebecca A. Taylor, PharmD, MBA, BCPS, FASHP; taylorra4@upmc.edu                   | 1.0        | 641                    | 503                      | 77                                     | 4.46                | 4.44                           | 4.46                                | 4.45                              | 4.46                            | 4.44  | 4.35                              | 4.35  | 4.43                    | AI + technologies   | Best Practices                                 |  |
| <b>October 23, 2025:</b> Stopping the Bleed in 2025: An Anticoagulation Reversal and Hemostasis Update   | Michael Gulseth, PharmD, BCPS, FMSHP, FASHP; michael.gulseth@sanfordhealth.org    | 1.0        | 662                    | 508                      | 68                                     | 4.39                | 4.38                           | 4.36                                | 4.38                              | 4.33                            | 4.33  | 4.25                              | 4.33  | 4.34                    | Anticoagulation     | Best Practices                                 |  |
| <b>November 19, 2025:</b> From Guidelines to Bedside: Evolving HIV Care in Hospitalized Patients   | Shannon Balcombe, PharmD, BCPS, AAHIVP; sbalcombe@health.ucsd.edu                 | 1.0        | 621                    | 471                      | 70                                     | 4.35                | 4.37                           | 4.38                                | 4.39                              | 4.35                            | 4.37  | 4.31                              | 4.38  | 4.36                    | HIV/AIDS            | Best Practices                                 |  |
| <b>December 17, 2025:</b> Human Trafficking from a Pharmacy Perspective (Working title)  | Anne Harring, PharmD; Anne_Harring@pba.edu; annieferri@yahoo.com                  | 1.0        | 544                    | 448                      | 68                                     | 4.41                | 4.39                           | 4.39                                | 4.39                              | 4.37                            | 4.37  | 4.29                              | 4.39  | 4.38                    | Administration      | Best Practices                                 |  |
|  | 4.4   |            |                        |                          |  |                     |                                |                                     |                                   |                                 |   |                                   |   |                         |                     |  |  |
|  |   | 12         | 8024                   | 6239                     |  |                     |                                |                                     |                                   |                                 |   |                                   |   |                         |                     |  |  |





Premier, Inc.  
Home-Study CE Evaluations Report - Pharmacists  
2025

| Date and Working Program Title  | Speaker Name, e-mail address   | Credit Hrs | Total # of Registrants | Total # of CE Recipients | # of Pharmacists Receiving CE | Objectives were met | Activity met educational needs | Quality of faculty was satisfactory | Educational materials were useful | Teaching methods were effective | Learning assessment activities were appropriate | Activity did not promote particular product or company | Overall Activity Rating | Specialty Areas          | Focus Areas (Outcomes, Safety, Best Practices) |
|---|--|------------|------------------------|--------------------------|-------------------------------|---------------------|--------------------------------|-------------------------------------|-----------------------------------|---------------------------------|---|--|-------------------------|--------------------------|--|
| <b>2022 Homestudy CE:</b> Addressing Pharmacy White-bagging at the State Level: How Providers can Engage to Impact Change               | Ken Komorny, PharmD, BCPS; kenneth.komorny@moffitt.org                                 | 1.0        | 219                    | 169                      | 109                           | 4.63                | 4.62                           | 4.65                                | 4.64                              | 4.64                            | 4.63  | 4.65   | 4.64                    | Pharmacy Law             | Best Practices                                 |
| <b>2022 Homestudy CE:</b> At Your Disposal: Safe and Compliant Pharmaceutical Waste   | Bryan C. McCarthy, Jr., PharmD, MS, MJ, FASHP; BMcCarthy@Lifespan.org                  | 1.0        | 326                    | 240                      | 134                           | 4.60                | 4.57                           | 4.59                                | 4.58                              | 4.58                            | 4.59  | 4.62   | 4.59                    | Pharmacy Law             | Best Practices                                 |
| <b>2022 Homestudy CE:</b> Best Practices for Controlled Substance Diversion Prevention  | Amisha Arya, PharmD, BCSCP; amisha.arya@nyulangone.org                                 | 1.0        | 183                    | 144                      | 87                            | 4.59                | 4.58                           | 4.59                                | 4.56                              | 4.57                            | 4.58  | 4.61   | 4.58                    | Pharmacy Administration  | Best Practices                                 |
| <b>2022 Homestudy CE:</b> Best Practices Utilizing Diabetes Technology Through Transitions of Care                                      | Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCEs, FADCEs, FCCP; dianamisaacs@gmail.com | 1.0        | 341                    | 237                      | 128                           | 4.63                | 4.63                           | 4.64                                | 4.6                               | 4.59                            | 4.6   | 4.63   | 4.62                    | Disease State Management | Best Practices                                 |
| <b>2022 Homestudy CE:</b> CMS Conditions of Participation: Integration into Accreditation Standards                                     | Patricia C. Kienle, RPh, MPA, BCSCP, FASHP; Patricia.Kienle@cardinalhealth.com         | 1.0        | 113                    | 75                       | 44                            | 4.66                | 4.61                           | 4.62                                | 4.62                              | 4.62                            | 4.62  | 4.64   | 4.63                    | Pharmacy Law             | Best Practices                                 |
| <b>2022 Homestudy CE:</b> Establishment and Impact of Clinical Pharmacy Services in an Accountable Care Organization in a Health System | Genevieve Kumapley, PharmD, BCOP; gkumapley@holynamae.org                              | 1.0        | 98                     | 87                       | 45                            | 4.59                | 4.62                           | 4.6                                 | 4.62                              | 4.61                            | 4.61  | 4.61   | 4.61                    | Pharmacy Administration  | Best Practices                                 |
| <b>2022 Homestudy CE:</b> Implementation of a system-wide remote patient monitoring program: increasing access with success             | Cathleen Mathew, PharmD, CDE, AE-C; cathleen.mathew@mountsinai.org                     | 1.0        | 108                    | 74                       | 39                            | 4.61                | 4.58                           | 4.63                                | 4.61                              | 4.6                             | 4.58  | 4.59   | 4.61                    | Pharmacy Administration  | Best Practices                                 |
|   | 4.64   |            |                        |                          |                               |                     |                                |                                     |                                   |                                 |   |  |                         |                          |  |
| <b>2022 Homestudy CE:</b> Improving Nephrotoxin Stewardship by Utilization of Clinical Surveillance                                     | Sandra Kane-Gill, PharmD, MSc, FCCM, FCCP; kane-gill@pitt.edu                          | 1.0        | 113                    | 55                       | 35                            | 4.64                | 4.62                           | 4.62                                | 4.6                               | 4.59                            | 4.59  | 4.68   | 4.62                    | Patient Safety           | Safety   |
| <b>2022 Homestudy CE:</b> Managing Acute Pain in Opioid Use Disorder  | Lee Kral, PharmD, BCPS, CPE; lee-kral@uiowa.edu  | 1.0        | 222                    | 132                      | 89                            | 4.61                | 4.61                           | 4.61                                | 4.61                              | 4.61                            | 4.6   | 4.6  | 4.61                    | Pain Management          | Best Practices                                 |
| <b>2022 Homestudy CE:</b> Medication Safety and Regulatory Compliance in Ambulatory Surgery Centers                                     | Victor Alves, PharmD, BCGP, FASCP; mailto:valves@octariusrx.com                        | 1.0        | 77                     | 66                       | 33                            | 4.57                | 4.56                           | 4.56                                | 4.55                              | 4.56                            | 4.55  | 4.57   | 4.56                    | Patient Safety           | Safety   |
| <b>2022 Homestudy CE:</b> Pharmacy Law and Ethics   | Keith Yoshizuka, PharmD, MBA, JD, FCSHP; kyoshizu@touro.edu                            | 1.0        | 142                    | 90                       | 57                            | 4.63                | 4.63                           | 4.65                                | 4.61                              | 4.63                            | 4.63  | 4.64   | 4.63                    | Pharmacy Law             | Best Practices                                 |
| <b>2022 Homestudy CE:</b> Strategies to Enhance and Expand Your Antimicrobial Stewardship Program                                       | Yi Guo, PharmD, BCIDP, yiguo@montefiore.org  | 1.0        | 149                    | 133                      | 70                            | 4.66                | 4.68                           | 4.61                                | 4.66                              | 4.66                            | 4.66  | 4.68   | 4.66                    | Pharmacy Administration  | Best Practices                                 |
| <b>2022 Homestudy CE:</b> Successful Management of Formulary Decisions – Controlling Costs Without Compromising Outcomes                | Pavel Goriacko, PharmD, MPH, BCPS; pgoriack@montefiore.org                             | 1.0        | 96                     | 87                       | 46                            | 4.62                | 4.60                           | 4.62                                | 4.60                              | 4.61                            | 4.61  | 4.61   | 4.61                    | Pharmacy Administration  | Best Practices                                 |
|   | 4.59   |            |                        |                          |                               |                     |                                |                                     |                                   |                                 |   |  |                         |                          |  |
| <b>2022 Homestudy CE:</b> The Use of SGLT2 Inhibitors for Heart Failure Management  | Judy Cheng, PharmD, MPH, FCCP, BCPS, RPh; judy.cheng@mcphs.edu                         | 1.0        | 410                    | 315                      | 227                           | 4.63                | 4.63                           | 4.63                                | 4.62                              | 4.63                            | 4.63  | 4.63   | 4.63                    | Disease State Management | Best Practices                                 |
| <b>2023 Home-Study CE:</b> 2023 Accreditation Update  | Patricia C. Kienle, RPh, MPA, FASHP; Patricia.Kienle@cardinalhealth.com                | 1.0        | 207                    | 160                      | 89                            | 4.55                | 4.54                           | 4.55                                | 4.51                              | 4.53                            | 4.52  | 4.56   | 4.54                    | Pharmacy Law             | Best Practices                                 |
| <b>2023 Home-Study CE:</b> A Joint Commission Primer: It's No Pain at All, When You Follow the Standards                                | Genevieve Kumapley, PharmD, BCOP; gkumapley@holynamae.org                              | 1.0        | 179                    | 151                      | 85                            | 4.56                | 4.57                           | 4.58                                | 4.57                              | 4.57                            | 4.59  | 4.61   | 4.58                    | Pain Management          | Best Practices                                 |
| <b>2023 Home-Study CE:</b> Managing Drug Shortages with a Medication Safety Perspective   | Kathy Ghomeshi, PharmD, MBA, BCPS, CPPS; kg-rx@ghomeshi.com                            | 1.0        | 272                    | 239                      | 141                           | 4.63                | 4.61                           | 4.62                                | 4.62                              | 4.61                            | 4.61  | 4.62   | 4.62                    | Patient Safety           | Safety   |
| <b>2023 Homestudy CE:</b> Optimizing Use of Novel Agents to Treat Multidrug-resistant Gram-negative Infections                          | Ryan K. Shields, PharmD, MS; shieldsrk@upmc.edu  | 1.0        | 189                    | 144                      | 87                            | 4.66                | 4.68                           | 4.69                                | 4.67                              | 4.67                            | 4.67  | 4.65   | 4.67                    | Disease State Management | Best Practices                                 |
| <b>2023 Home-Study CE:</b> Perioperative Antimicrobial Stewardship and Pharmacy's Role  | Sara Jordan Hyland, PharmD, BCCCP; Sara.Jordan@ohiohealth.com                          | 1.0        | 233                    | 148                      | 77                            | 4.67                | 4.65                           | 4.65                                | 4.65                              | 4.64                            | 4.65  | 4.7  | 4.66                    | Disease State Management | Best Practices                                 |
| <b>2023 Home-Study CE:</b> Thrombolytics for Acute Ischemic Stroke: Have We Found the Right (Tenecte)Plase in Therapy?                  | Karen Berger, PharmD, FCCM, BCPS, BCCCP; karenberger7@gmail.com                        | 1.0        | 299                    | 213                      | 141                           | 4.67                | 4.65                           | 4.67                                | 4.66                              | 4.63                            | 4.64  | 4.66   | 4.65                    | Disease State Management | Best Practices                                 |
| <b>2023 Home-Study CE:</b> Updates in HIV Treatment and Prevention (HIV/AIDS)   | Melanie Berry, PharmD, BCACP; mberry2@bidmc.harvard.edu                                | 1.0        | 206                    | 143                      | 83                            | 4.6                 | 4.59                           | 4.6                                 | 4.59                              | 4.58                            | 4.61  | 4.61   | 4.60                    | AIDS Therapy             | Best Practices                                 |
| <b>2024 Home-Study CE:</b> Reversal of Direct Factor-Xa Inhibitors, An Evidence Update  | Michael P. Gulseth, Pharm. D., BCPS, FMSHP, FASHP; michael.gulseth@sanfordhealth.org   | 1.0        | 221                    | 120                      | 85                            | 4.65                | 4.63                           | 4.66                                | 4.63                              | 4.62                            | 4.65  | 4.68   | 4.65                    | Disease State Management | Best Practices                                 |
| <b>2024 Home-Study CE:</b> 2024-2025 Influenza Virus and Vaccine Update   | Premier Staff  | 1.0        | 244                    | 167                      | 101                           | 4.68                | 4.69                           | 4.65                                | 4.69                              | 4.67                            | 4.67  | 4.69   | 4.68                    | Immunizations            | Best Practices                                 |
| <b>2025 Home-Study CE:</b> 2025-2026 Influenza Virus and Vaccine Update   | Premier Staff  | 1.0        | 133                    | 87                       | 59                            | 4.69                | 4.67                           | 4.66                                | 4.67                              | 4.66                            | 4.68  | 4.68   | 4.67                    | Immunizations            | Best Practices                                 |

Premier, Inc.  
Home-Study CE Evaluations Report - Pharmacy Technicians  
2025

| Date and Working Program Title  | Speaker Name, e-mail address   | Credit Hrs | Total # of Registrants | Total # of CE Recipients | # of Pharmacy Technicians Receiving CE | Objectives were met | Activity met educational needs | Quality of faculty was satisfactory | Educational materials were useful | Teaching methods were effective | Learning assessment activities were appropriate | Activity did not promote particular product or company | Overall Activity Rating | Specialty Areas          | Focus Areas (Outcomes, Safety, Best Practices) |
|---|--|------------|------------------------|--------------------------|--|---------------------|--------------------------------|-------------------------------------|-----------------------------------|---------------------------------|---|--|-------------------------|--------------------------|--|
| <b>2022 Homestudy CE:</b> Addressing Pharmacy White-bagging at the State Level: How Providers can Engage to Impact Change               | Ken Komorny, PharmD, BCPS; kenneth.komorny@moffitt.org                                 | 1.0        | 219                    | 169                      | 60                                     | 4.36                | 4.38                           | 4.38                                | 4.36                              | 4.34                            | 4.38  | 4.38   | 4.37                    | Pharmacy Law             | Best Practices                                 |
| <b>2022 Homestudy CE:</b> At Your Disposal: Safe and Compliant Pharmaceutical Waste   | Bryan C. McCarthy, Jr., PharmD, MS, MJ, FASHP; BMCCarthy@Lifespan.org                  | 1.0        | 326                    | 240                      | 106                                    | 4.41                | 4.39                           | 4.39                                | 4.37                              | 4.36                            | 4.38  | 4.40   | 4.39                    | Pharmacy Law             | Best Practices                                 |
| <b>2022 Homestudy CE:</b> Best Practices for Controlled Substance Diversion Prevention  | Amisha Arya, PharmD, BCSCP; amisha.arya@nyulangone.org                                 | 1.0        | 183                    | 144                      | 57                                     | 4.44                | 4.42                           | 4.43                                | 4.40                              | 4.44                            | 4.43  | 4.41   | 4.42                    | Pharmacy Administration  | Best Practices                                 |
| <b>2022 Homestudy CE:</b> Best Practices Utilizing Diabetes Technology Through Transitions of Care                                      | Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCEs, FADCEs, FCCP; dianamisaacs@gmail.com | 1.0        | 341                    | 237                      | 109                                    | 4.46                | 4.48                           | 4.49                                | 4.50                              | 4.48                            | 4.46  | 4.48   | 4.48                    | Disease State Management | Best Practices                                 |
| <b>2022 Homestudy CE:</b> CMS Conditions of Participation: Integration into Accreditation Standards                                     | Patricia C. Kienle, RPh, MPA, BCSCP, FASHP; Patricia.Kienle@cardinalhealth.com         | 1.0        | 113                    | 75                       | 31                                     | 4.48                | 4.45                           | 4.50                                | 4.48                              | 4.45                            | 4.49  | 4.47   | 4.47                    | Pharmacy Law             | Best Practices                                 |
| <b>2022 Homestudy CE:</b> Establishment and Impact of Clinical Pharmacy Services in an Accountable Care Organization in a Health System | Genevieve Kumapley, PharmD, BCOP; gkumapley@holyname.org                               | 1.0        | 98                     | 87                       | 42                                     | 4.51                | 4.47                           | 4.49                                | 4.50                              | 4.48                            | 4.48  | 4.51   | 4.49                    | Pharmacy Administration  | Best Practices                                 |
| <b>2022 Homestudy CE:</b> Implementation of a system-wide remote patient monitoring program: increasing access with success             | Cathleen Mathew, PharmD, CDE, AE-C; cathleen.mathew@mountsinai.org                     | 1.0        | 108                    | 74                       | 35                                     | 4.48                | 4.50                           | 4.49                                | 4.46                              | 4.45                            | 4.49  | 4.49   | 4.48                    | Pharmacy Administration  | Best Practices                                 |
|   | Ruchi Tiwari, PharmD, MS; ruchi.tiwari@mountsinai.org                                  |            |                        |                          |  |                     |                                | 4.49                                |                                   |                                 |   |  |                         |                          |  |
| <b>2022 Homestudy CE:</b> Improving Nephrotoxin Stewardship by Utilization of Clinical Surveillance                                     | Sandra Kane-Gill, PharmD, MSc, FCCM, FCCP; kane-gill@pitt.edu                          | 1.0        | 113                    | 55                       | 20                                     | 4.47                | 4.41                           | 4.44                                | 4.46                              | 4.45                            | 4.45  | 4.46   | 4.45                    | Patient Safety           | Safety   |
| <b>2022 Homestudy CE:</b> Managing Acute Pain in Opioid Use Disorder  | Lee Kral, PharmD, BCPS, CPE; lee-kral@uiowa.edu  | 1.0        | 222                    | 132                      | 43                                     | 4.53                | 4.49                           | 4.54                                | 4.51                              | 4.52                            | 4.51  | 4.53   | 4.52                    | Pain Management          | Best Practices                                 |
| <b>2022 Homestudy CE:</b> Medication Safety and Regulatory Compliance in Ambulatory Surgery Centers                                     | Victor Alves, PharmD, BCGP, FASCP; mailto:valves@octariusrx.com                        | 1.0        | 77                     | 66                       | 33                                     | 4.45                | 4.45                           | 4.45                                | 4.45                              | 4.44                            | 4.46  | 4.41   | 4.44                    | Patient Safety           | Safety   |
| <b>2022 Homestudy CE:</b> Pharmacy Law and Ethics   | Keith Yoshizuka, PharmD, MBA, JD, FCSHP; kyoshizu@touro.edu                            | 1.0        | 142                    | 90                       | 33                                     | 4.50                | 4.50                           | 4.48                                | 4.46                              | 4.48                            | 4.50  | 4.47   | 4.48                    | Pharmacy Law             | Best Practices                                 |
| <b>2022 Homestudy CE:</b> Strategies to Enhance and Expand Your Antimicrobial Stewardship Program                                       | Yi Guo, PharmD, BCIDP, yiguo@montefiore.org  | 1.0        | 149                    | 133                      | 63                                     | 4.36                | 4.36                           | 4.43                                | 4.38                              | 4.30                            | 4.37  | 4.36   | 4.37                    | Pharmacy Administration  | Best Practices                                 |
| <b>2022 Homestudy CE:</b> Successful Management of Formulary Decisions – Controlling Costs Without Compromising Outcomes                | Pavel Goriacko, PharmD, MPH, BCPS; pgoriack@montefiore.org                             | 1.0        | 96                     | 87                       | 41                                     | 4.52                | 4.48                           | 4.52                                | 4.52                              | 4.52                            | 4.52  | 4.52   | 4.52                    | Pharmacy Administration  | Best Practices                                 |
|   | Janelle Duran, PharmD, BCPS; janelle.duran@commonspirit.org                            |            |                        |                          |  |                     |                                | 4.52                                |                                   |                                 |   |  |                         |                          |  |
| <b>2022 Homestudy CE:</b> The Use of SGLT2 Inhibitors for Heart Failure Management  | Judy Cheng, PharmD, MPH, FCCP, BCPS, RPh; judy.cheng@mcphs.edu                         | 1.0        | 410                    | 315                      | 88                                     | 4.40                | 4.34                           | 4.40                                | 4.38                              | 4.38                            | 4.38  | 4.38   | 4.38                    | Disease State Management | Best Practices                                 |
| <b>2023 Home-Study CE:</b> 2023 Accreditation Update  | Patricia C. Kienle, RPh, MPA, FASHP; Patricia.Kienle@cardinalhealth.com                | 1.0        | 207                    | 160                      | 71                                     | 4.36                | 4.36                           | 4.36                                | 4.33                              | 4.33                            | 4.32  | 4.39   | 4.35                    | Pharmacy Law             | Best Practices                                 |
| <b>2023 Home-Study CE:</b> A Joint Commission Primer: It's No Pain at All, When You Follow the Standards                                | Genevieve Kumapley, PharmD, BCOP; gkumapley@holyname.org                               | 1.0        | 179                    | 151                      | 66                                     | 4.37                | 4.35                           | 4.36                                | 4.38                              | 4.36                            | 4.38  | 4.36   | 4.37                    | Pain Management          | Best Practices                                 |
| <b>2023 Home-Study CE:</b> Managing Drug Shortages with a Medication Safety Perspective   | Kathy Ghomeshi, PharmD, MBA, BCPS, CPPS; kg-rx@ghomeshi.com                            | 1.0        | 272                    | 239                      | 98                                     | 4.46                | 4.45                           | 4.46                                | 4.45                              | 4.42                            | 4.44  | 4.44   | 4.45                    | Patient Safety           | Safety   |
| <b>2023 Homestudy CE:</b> Optimizing Use of Novel Agents to Treat Multidrug-resistant Gram-negative Infections                          | Ryan K. Shields, PharmD, MS; shieldsrk@upmc.edu  | 1.0        | 189                    | 144                      | 57                                     | 4.38                | 4.41                           | 4.4                                 | 4.41                              | 4.39                            | 4.39  | 4.41   | 4.40                    | Disease State Management | Best Practices                                 |
| <b>2023 Home-Study CE:</b> Perioperative Antimicrobial Stewardship and Pharmacy's Role  | Sara Jordan Hyland, PharmD, BCCCP; Sara.Jordan@ohiohealth.com                          | 1.0        | 233                    | 148                      | 71                                     | 4.37                | 4.32                           | 4.35                                | 4.38                              | 4.36                            | 4.38  | 4.42   | 4.37                    | Disease State Management | Best Practices                                 |
| <b>2023 Home-Study CE:</b> Thrombolytics for Acute Ischemic Stroke: Have We Found the Right (Tenecte)Plase in Therapy?                  | Karen Berger, PharmD, FCCM, BCPS, BCCCP; karenberger7@gmail.com                        | 1.0        | 299                    | 213                      | 72                                     | 4.5                 | 4.45                           | 4.48                                | 4.51                              | 4.48                            | 4.48  | 4.49   | 4.48                    | Disease State Management | Best Practices                                 |
| <b>2023 Home-Study CE:</b> Updates in HIV Treatment and Prevention (HIV/AIDS)   | Melanie Berry, PharmD, BCACP; mberry2@bidmc.harvard.edu                                | 1.0        | 206                    | 143                      | 60                                     | 4.38                | 4.39                           | 4.4                                 | 4.39                              | 4.39                            | 4.39  | 4.4  | 4.39                    | AIDS Therapy             | Best Practices                                 |
| <b>2024 Home-Study CE:</b> Reversal of Direct Factor-Xa Inhibitors, An Evidence Update  | Michael P. Gulseth, Pharm. D., BCPS, FMSHP, FASHP; michael.gulseth@sanfordhealth.org   | 1.0        | 221                    | 120                      | 35                                     | 4.27                | 4.27                           | 4.27                                | 4.24                              | 4.27                            | 4.3   | 4.32   | 4.28                    | Disease State Management | Best Practices                                 |









Premier, Inc.  
Premier Member Meeting CE Evaluations Report  
2025

| Date and Program Title   | Speaker Name, e-mail address               | Credit Hrs | Total # of Registrants | Total # of CE Recipients | # of Pharmacy Technicians Receiving CE | Objectives were met | Activity met educational needs | Quality of faculty was satisfactory | Educational materials were useful | Teaching methods were effective | Learning assessment activities were appropriate | Activity did not promote product or company | Overall Activity Rating | Specialty Areas | Focus Areas (Outcomes, Safety, Best Practices) |
|--|--|------------|------------------------|--------------------------|--|---------------------|--------------------------------|-------------------------------------|-----------------------------------|---------------------------------|---|---|-------------------------|-----------------|--|
| <b>October 28, 2025:</b> Navigating 340B in Maryland in Financial Headwinds          | Jason Reddish; Jason.Reddish@PowersLaw.com | 1.0        | 6                      | 6                        | -                                      | 4.83                | 4.67                           | 4.83                                | 4.83                              | 4.83                            | 4.83  | 4.83  | 4.81                    | 340B            | Best Practices                                 |
| <b>November 6, 2025:</b> The Intersection of Pharmacy & Policy: Washington DC Update | Soumi Saha; soumi_saha@premierinc.com      | 1.0        | 18                     | 18                       | -                                      | 4.61                | 4.61                           | 4.61                                | 4.61                              | 4.67                            | 4.67  | 4.67  | 4.64                    | Pharmacy Law    | Best Practices                                 |

Premier, Inc.  
CE Teleconference Comments Report - Pharmacists  
2025

| Date and Activity Topic  | Speaker(s)  | Total # of Registrants | Total # of Participants receiving CE credit | # of Pharmacists receiving CE credit | Bias, promotion or commercial advertisement?      | Comments (number of members with same response in parentheses)  |
|--|---|------------------------|---|--------------------------------------|---|---|
| <b>January 23, 2025:</b> 340B Program – Looking Forward to 2025 After Another Tumultuous Year  | Jason B. Reddish; Jason.Reddish@PowersLaw.com                                     | 845                    | 622   | 526                                  | NA/None (102)                                     | 1. Clear/Concise; 2. Could have been longer; 3. Engaging (2); 4. Good; 5. Good/Very good/Great/Excellent presentation (4); 6. Good/Very good/Great/Excellent speaker (4); 7. Fantastic presentation; 8. Good job; 9. Good topic; 10. Knowledgeable (3); 11. Thank you (5); 12. Thorough; 13. Very important topic; Very informative (3)   |
| <b>February 25, 2025:</b> Clean Data and Polished Compliance: Leveraging AI Diversion Software to Optimize Alerts and Improve Controlled Substance Processes | Bethanie Gamble, PharmD; Bethanie.Gamble@prismahealth.org                         | 689                    | 526   | 447                                  | NA/None (73)                                      | 1. Engaging; 2. Good/Very good/Great/Excellent (3); 3. Good/Very good/Great/Excellent presentation (3); 4. Good job; 5. Informative (2); 6. Knowledgeable; 7. Slides not well put together; 8. Thank you; 9. Too much information; 10. Very detailed  |
| <b>March 27, 2025:</b> Don't Get Lost in the Alphabet Soup: Overview of Emerging Cancer Immune Therapies   | Genevieve Kumapley, PharmD, BCOP; gkumapley@holynome.org                          | 714                    | 542   | 468                                  | NA/None (69); CAR-T brand name products mentioned | 1. Very deep topic; 2. Awesome (3); 3. Clear/Concise (4); 4. Effective speaker; 5. Engaging; 6. Good/Very good/Great/Excellent (10); 7. Good/Very good/Great/Excellent presentation (10); 8. Good/Very good/Great/Excellent speaker (7); 9. Great explanations; 10. Great job; 11. Informative (14); 12. Interesting (7); 13. Knowledgeable (7); 14. Not enough time (5); 15. One of the best CEs I've attended; 16. Outstanding job; 17. Thank you (3); 18. Thorough (3); 19. Well constructed; 20. Well done; 21. Well organized  |
| <b>April 23, 2025:</b> Health Equity in Practice: Addressing Bias and Social Drivers for Better Patient Outcomes   | Sally A. Arif, PharmD, BCCP; sarif@midwestern.edu                                 | 697                    | 520   | 441                                  | NA/None (63)                                      | 1. Amazing; 2. Clear/Concise; 3. Easy to follow; 4. Engaging (4); 5. Entertaining; 6. Good/Very good/Great/Excellent (6); 7. Good/Very good/Great/Excellent presentation (4); 8. Good/Very good/Great/Excellent speaker (9); 9. Great examples/activities provided; 10. Great references provided; 11. Helpful; 12. Informative (10); 13. Interesting (4); 14. Knowledgeable (7); 15. Sensible flow of presentation; 16. Thank you (2); 17. Thanks for the Harvard bias test links—they'll be great teaching tools for staff and interns; 18. Too much focus on provider bias; 19. Useful information; 19. Well done  |
| <b>May 29, 2025:</b> How It's Made: 503B Product Ingredients and Sterilization Methods   | Kevin N. Hansen, PharmD, MS, BCSCP; kevin_hansen@premierinc.com                   | 753                    | 557   | 483                                  | NA/None (77)                                      | 1. Amazing; 2. Clear/Concise (4); 3. Cool stuff; 4. Easy to follow; 5. Easy to understand (2); 6. Engaging (2); 7. Enjoyable; 8. Entertaining; 9. Good/Very good/Great/Excellent (11); 10. Good/Very good/Great/Excellent presentation (11); 11. Good/Very good/Great/Excellent speaker (12); 12. Spoke very eloquently; 13. Informative (13); 14. Interesting (2); 15. Very knowledgeable (14); 16. Practical information; 17. Relevant and timely; 18. Thank you (2); 19. Very thorough; 20. Well done; 21. Well organized (2)  |
| <b>June 17, 2025:</b> Incorporating Anti-Amyloid-β (Aβ) Monoclonal Antibody Therapies into Alzheimer's Disease Management                                    | Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP; marketa.marvanova@pacificu.edu | 686                    | 517   | 429                                  | NA/None (68)                                      | 1. Easy to follow along; 2. Enlightening; 3. Good/Very good/Great/Excellent (9); 4. Good/Very good/Great/Excellent presentation (9); 5. Good/Very good/Great/Excellent speaker (8); 6. Great job (3); 7. Include a patient case for real-life application; 8. Informative (15); 9. Interesting (2); 10. Knowledgeable (9); 11. Nice job (2); 12. Professional; 13. Thorough; 14. Very engaging; 15. Well done   |
| <b>July 23, 2025:</b> Specialty, Oncology, and ID Drugs: What is in the Pipeline? - The 2025 Update  | Liya Davydov, PharmD, BCPS, BCGP; Liya_Davydov@premierinc.com                     | 474                    | 361   | 296                                  | NA/None (45)                                      | 1. Clear/Concise; 2. Effective; 3. Good/Very good/Great/Excellent (4); 4. Good/Very good/Great/Excellent speaker (5); 5. Good/Very good/Great/Excellent presentation (4); 6. Good/Very good/Great job (2); 7. Helpful (2); 8. Informative (10); 9. Knowledgeable (7); 10. Interesting; 11. Nice; 12. Should present at a slower pace; 13. Thorough; 14. Too much information (3); 15. Very impressive overview; 16. Thanks; 17. Well prepared; 18. Well versed  |
| <b>August 13, 2025:</b> Biosimilars -The 2025 Update   | Liya Davydov, PharmD, BCPS, BCGP; Liya_Davydov@premierinc.com                     | 698                    | 665   | 584                                  | NA/None (73)                                      | 1. A legend with asterisks on each slide would be useful; 2. A lot to absorb; 3. Clear/Concise (2); 4. Cutting edge; 5. Dense content; 6. Easy to listen to; 7. Enthusiastic; 8. Good/Very good/Great/Excellent (10); 9. Good/Very good/Great/Excellent presentation (9); 10. Good/Very good/Great/Excellent speaker (7); 11. Great job; 12. Helpful (2); 13. Enjoyed the presentation; 14. Informative (11); 15. Interesting; 16. Knowledgeable (13); 17. more emphasis on interchangeability and practical real-life scenario info; 18. More foundational knowledge at the beginning of the CE; 19. Nice job; 20. Passionate; 21. Presentation met expectations; 22. Professional; 23. Structure was not great or helpful; 24. Succinct (2); 25. Thank you (3); 26. Good tools; 27. Well done (3); 28. Well organized |
| <b>September 18, 2025:</b> Leading with Intelligence: Embracing AI to Advance Pharmacy   | Rebecca A. Taylor, PharmD, MBA, BCPS, FASHP; taylorra4@upmc.edu                   | 641                    | 503   | 426                                  | NA/None (64)                                      | 1. Clear/Concise (4); 2. Engaging (2); 3. Examples would have been helpful; 4. Good/Very good/Great/Excellent (8); 5. Good/Very good/Great/Excellent presentation (6); 6. Good/Very good/Great/Excellent speaker (7); 7. Good pace; 8. Great insight; 9. Great job (2); 10. Great update; 11. Informative (16); 12. Interesting (2); 13. Knowledgeable (9); 14. Thank you (3); 15. Very organized; 16. Well presented   |
| <b>October 23, 2025:</b> Stopping the Bleed in 2025: An Anticoagulation Reversal and Hemostasis Update   | Michael Gulseth, PharmD, BCPS, FMSHP, FASHP; michael.gulseth@sanfordhealth.org    | 662                    | 508   | 440                                  | NA/None (77)                                      | 1. A lot to cover; 2. Amazing job; 3. Amazing presentation; 4. Clear/Concise (5); 5. Easy to follow; 6. Engaging (3); 7. Good/Very good/Great/Excellent (9); 8. Good/Very good/Great/Excellent presentation (8); 9. Good/Very good/Great/Excellent speaker (12); 10. Great practical perspective; 11. Informative (16); 12. Interesting; 13. Knowledgeable (15); 14. Thank you (4); 15. Very detailed; 16. Very nice job; 17. Very organized; 18. Very thorough; 19. Very up to date; 20. Well done   |
| <b>November 19, 2025:</b> From Guidelines to Bedside: Evolving HIV Care in Hospitalized Patients   | Shannon Balcombe, PharmD, BCPS, AAHIVP; sbalcombe@health.ucsd.edu                 | 621                    | 471   | 401                                  | NA/None (56)                                      | 1. Clear/Concise (3); 2. Cool stuff; 3. Cutting-edge information; 4. Easy to follow; 5. Effective in delivery of subject; 6. Engaging; 7. Good/Very good/Great/Excellent (5); 8. Good/Very good/Great/Excellent presentation (7); 9. Good/Very good/Great/Excellent speaker (9); 10. Great job; 11. Incredible speaker; 12. Informative (15); 13. Interesting; 14. Knowledgeable (8); 15. Thank you; 16. Thorough; 17. Well organized   |
| <b>December 17, 2025:</b> Human Trafficking from a Pharmacy Perspective (Working title)  | Anne Harring, PharmD; Anne_Harring@pba.edu; annieferrri@yahoo.com                 | 544                    | 448   | 380                                  | NA/None (57)                                      | 1. A bold presentation; 2. Appropriate tone and pace; 3. Clear/Concise (2); 4. Contacting the Trafficking Hotline is time consuming; 5. Engaging; 6. Good/Very good/Great/Excellent (8); 7. Good/Very good/Great/Excellent presentation (4); 8. Good/Very good/Great/Excellent speaker (5); 9. Good job; 10. Important topic (2); 11. Informative (9); 12. Interesting (6); 13. Nice job (2); 14. Passionate; 15. Pertinent and pharmacy focused; 16. Well done; 17. Well organized   |
|  | Yasmin Grace, BS, PharmD; Yasmin_Grace@pba.edu                                    |                        |   |                                      |   | 1. Amazing job; 2. Appropriate tone and pace; 3. Clear/Concise; 4. Engaging; 5. Good/Very good/Great/Excellent; 6. Good/Very good/Great/Excellent presentation (2); 7. Good job; 8. Good/Very good/Great/Excellent speaker (5); 8. I enjoyed it; 9. Informative (10); 11. Interesting (5); 12. Knowledgeable; 13. Nice job (3); 14. Well organized (2); 15. Important topic   |

Premier, Inc.  
CE Teleconference Comments Report - Pharmacy Technicians  
2025

| Date and Activity Topic  | Speaker(s)  | Total # of Registrants  | Total # of Participants receiving CE credit | # of Pharmacy Techs receiving CE credit | Bias, promotion or commercial advertisement? | Comments (number of members with same response in parentheses)  |
|--|---|---|---|---|--|---|
| <b>January 23, 2025:</b> 340B Program – Looking Forward to 2025 After Another Tumultuous Year  | Jason B. Reddish; Jason.Reddish@PowersLaw.com                                     | 845   | 622   | 96                                      | NA/None (9)                                  | 1. Well done  |
| <b>February 25, 2025:</b> Clean Data and Polished Compliance: Leveraging AI Diversion Software to Optimize Alerts and Improve Controlled Substance Processes | Bethanie Gamble, PharmD; Bethanie.Gamble@prismahealth.org                         | 689   | 526   | 79                                      | NA/None (7)                                  | 1. Great presentation; 2. Informative and constructive; 3. Insightful; 4. Good  |
| <b>March 27, 2025:</b> Don't Get Lost in the Alphabet Soup: Overview of Emerging Cancer Immune Therapies   | Genevieve Kumapley, PharmD, BCOP; gkumapley@holyname.org                          | 714   | 542   | 74                                      | NA/None (9)                                  | 1. Great job; 2. Not enough time; 3. Very good (2); 4. Great presentation; 5. Interesting; 6. Excellent speaker (2); 7. Knowledgeable   |
| <b>April 23, 2025:</b> Health Equity in Practice: Addressing Bias and Social Drivers for Better Patient Outcomes   | Sally A. Arif, PharmD, BCCP; sarif@midwestern.edu                                 | 697   | 520   | 79                                      | NA/None (7)                                  | 1. Good/Very good/Great/Excellent speaker (2); 2. Nice (2); 3. Great explanations; 4. Interesting; 5. Informative   |
| <b>May 29, 2025:</b> How It's Made: 503B Product Ingredients and Sterilization Methods   | Kevin N. Hansen, PharmD, MS, BCSCP; kevin_hansen@premierinc.com                   | 753   | 557   | 74                                      | NA/None (7)                                  | 1. Informative (2); 2. Clear/Concise (2); 3. Interesting; 4. Excellent speaker; 5. Thank you; 6. Very thorough  |
| <b>June 17, 2025:</b> Incorporating Anti-Amyloid-β (Aβ) Monoclonal Antibody Therapies into Alzheimer's Disease Management                                    | Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP; marketa.marvanova@pacificu.edu | 686   | 517   | 88                                      | NA/None (7)                                  | 1. Good (2); 2. Interesting; 3. Excellent speaker; 4. Clear/Concise (3); 5. Knowledgeable (2)   |
| <b>July 23, 2025:</b> Specialty, Oncology, and ID Drugs: What is in the Pipeline? - The 2025 Update  | Liya Davydov, PharmD, BCPS, BCGP; Liya_Davydov@premierinc.com                     | 474   | 361   | 65                                      | NA/None (10)                                 | 1. Knowledgeable (2); 2. Informative (3); 3. Helpful; 4. Thank you; 5. Excellent speaker; 6. Clear/Concise (2); 7. Thorough (2); 8. Interesting                               |
| <b>August 13, 2025:</b> Biosimilars -The 2025 Update   | Liya Davydov, PharmD, BCPS, BCGP; Liya_Davydov@premierinc.com                     | 698   | 664   | 80                                      | NA/None (9)                                  | 1. Very informative (2); 2. Very thorough; 3. Excellent speaker; 4. Clear/Concise (2); 5. Interesting; 6. Thank you   |
| <b>September 18, 2025:</b> Leading with Intelligence: Embracing AI to Advance Pharmacy   | Rebecca A. Taylor, PharmD, MBA, BCPS, FASHP; taylorra4@upmc.edu                   | 641   | 503   | 77                                      | NA/None (10)                                 | 1. Good/Very good/Great Excellent presentation (2); 2. Calm speaker; 3. Easy to understand and follow; 4. Excellent speaker; 5. Clear/Concise; 6. Interesting; 7. Educational |
| <b>October 23, 2025:</b> Stopping the Bleed in 2025: An Anticoagulation Reversal and Hemostasis Update   | Michael Gulseth, PharmD, BCPS, FMSHP, FASHP; michael.gulseth@sanfordhealth.org    | 662   | 508   | 68                                      | NA/None (5)                                  | 1. Thorough with polling questions; 2. Excellent speaker; 3. Very knowledgeable; 4. Interesting   |
| <b>November 19, 2025:</b> From Guidelines to Bedside: Evolving HIV Care in Hospitalized Patients   | Shannon Balcombe, PharmD, BCPS, AAHVP; sbalcombe@health.ucsd.edu                  | 621   | 471   | 70                                      | NA/None (6)                                  | 1. Good content, although more tailored specifically for pharmacists; 2. Good/Very good/Great/Excellent speaker (2); 3. Clear/Concise (2); 4. Interesting                     |
| <b>December 17, 2025:</b> Human Trafficking from a Pharmacy Perspective (Working title)  | Anne Harring, PharmD; Anne_Harring@pba.edu; annieferri@yahoo.com                  | 544   | 448   | 68                                      | NA/None (6)                                  | 1. Great job; 2. Good/Very good/Great/Excellent speaker (2); 3. Interesting   |
|  | Yasmin Grace, BS, PharmD; Yasmin_Grace@pba.edu                                    | 1. Clear/Concise; 2. Good/Very good/Great/Excellent speaker (2); 3. Interesting |   |   |  |   |

Premier, Inc.  
Pharmacy Practice Forum Comments Reports  
2025

**Pharmacists**

| Date and Activity Topic  | Speaker(s)  | Total # of Registrants | Total # of Participants receiving CE credit | # of Pharmacists receiving CE credit | Bias, promotion or commercial advertisement (Pharmacists)? | Comments (number of members with same response in parentheses)  |
|--|---|------------------------|---|--------------------------------------|--|---|
| <b>February 11, 2025:</b> Creating a Practical Learning Plan: Effectively Balancing Work and Precepting Duties | Suzanne Higginbotham, PharmD BCACP, CDCES; Suzanne.Higginbotham@osumc.edu                         | 727                    | 543   | 482                                  | NA/None (71)   | 1. Clear/Concise; 2. Easy to listen to/understand (2); 3. Effective; 4. Engaging (2); 5. Good/Very good/Great/Excellent (12); 6. Good/Very good/Great/Excellent presentation (9); 7. Good/Very good/Great/Excellent speaker (8); 8. Great ideas; 9. Great job; 10. Informative (11); 11. Insightful (2); 12. Interesting (3); 13. Knowledgeable (5); 14. More case-based examples would have been helpful; 15. Thank you (8); 16. Thorough (3); 17. Very nice job; 18. Well done (2); 19. Well organized; 20. Wonderful ideas; 21. Wonderful presentation   |
| <b>April 15, 2025:</b> NIOSH Hazardous Drug Update: Strategies for Your Organization                           | Patricia C. Kienle, RPh, MPA, BCSCP, FASHP; patricia.kienle@cardinal.com                          | 861                    | 669   | 586                                  | NA/None (107)  | 1. Amazing (2); 2. Best speaker and presentation; 3. Clear/Concise (4); 4. Easy to listen to/understand (3); 5. Engaging (4); 6. Good/Very good/Great/Excellent (15); 7. Good/Very good/Great/Excellent presentation (11); 8. Good/Very good/Great/Excellent speaker (15); 9. Expert speaker (2); 10. Fantastic; 11. Great information to reinforce; 12. Helpful (3); 13. Important, practical advice; 14. Informative (26); 15. Interesting (3); 16. Knowledgeable (28); 17. More real-life examples of "heavy lifting"; 18. Nice presentation; 19. Not enough time to answer questions (2); 20. Relevant information (2); 21. Thank you (5); 22. Well organized (2); 23. Wonderful job, as always |
| <b>June 10, 2025:</b> Type 2 Diabetes: Medications, Monitoring, and Management                                 | Hilary Weismantel, PharmD, BCACP, BC-ADM; Hilary.Weismantel@sluhn.org; hilaryweismantel@gmail.com | 685                    | 530   | 464                                  | NA/None (76)   | 1. Amazing; 2. Awesome (2); 3. Clear/Concise (4); 4. Ease of delivery; 5. Easy to follow (3); 6. Easy to listen to; 7. Engaging (3); 8. Enlightening; 9. Good/Very good/Great/Excellent (9); 10. Good/Very good/Great/Excellent job (6); 11. Good/Very good/Great/Excellent presentation (12); 12. Good/Very good/Great/Excellent speaker (15); 13. Informative (12); 14. Interesting (2); 15. Knowledgeable (11); 16. Poor audio; 17. Professional; 18. Thank you (3); 19. Thorough (4); 20. Timely; 21. Useful information (2); 22. Valuable information; 23. Organized (3)   |
| <b>August 7 2025:</b> From Textbook to Tech: Interacting with the Gen Z Learner                                | Megan Adelman Elavsky, BCPS, BCGP, CDCES; ADELMAM2@ccf.org  | 638                    | 478   | 403                                  | NA/None (44)   | 1. Clear/Concise (2); 2. Effective; 3. Engaging (2); 4. Good/Very good/Great/Excellent (9); 5. Good/Very good/Great/Excellent speaker (5); 6. Great presentation (7); 7. Eye-opening; 8. Informative (12); 9. Knowledgeable; 10. Thank you (2); 11. Timely and accurate; 12. Very good job  |
| <b>October 8, 2025:</b> Pharmacy Services Enhancing Patient Outcomes in Transitions of Care                    | Brittany Symonds PharmD, BCACP; Brittany.Symonds@fairview.org                                     | 575                    | 465   | 405                                  | NA/None (62)   | 1. Clear/Concise (3); 2. Confident; 3. Enjoyable; 4. Good/Very good/Great/Excellent (10); 5. Good/Very good/Great/Excellent presentation (4); 6. Good/Very good/Great/Excellent speaker (7); 7. Good opportunity to answer questions; 8. Informative (12); 9. Interesting (2); 10. Knowledgeable (5); 11. Nice job; 12. Organized; 13. Professional; 14. Thank you (2); 15. Thorough; 16. Very detailed (2); 16. Well done  |
|  | Shana Steinbeck, PharmD, BCPS; Shana.Steinbeck@fairview.org                                       |                        |   |                                      |  | 1. Clear/Concise; 2. Detailed and organized; 3. Engaging; 4. Enjoyable; 5. Good/Very good/Great/Excellent (9); 6. Good/Very good/Great/Excellent presentation (6); 7. Good/Very good/Great/Excellent speaker (4); 8. Good opportunity to answer questions; 9. Informative (12); 10. Interesting; 11. Knowledgeable (6); 12. Nice job; 13. Professional (2); 14. Thank you (3); 15. Thorough; 16. Well done  |
| <b>December 2, 2025:</b> Preceptor Development: An AIRXC Collaborative Challenge                               | Frank Szczerba, PharmD, BCPS, BCPPS; frank.szczerba@baystatehealth.org                            | 533                    | 393   | 387                                  | NA/None (1)  | 1. Clear/Concise; 2. Easy to follow; 3. Engaging; 4. Good/Very good/Great/Excellent (10); 5. Good/Very good/Great/Excellent presentation (2); 6. Good/Very good/Great/Excellent speaker (4); 7. Good/Very good/Great/Excellent job (3); 8. Great content; 9. Informative (14); 10. Interesting (2); 11. Knowledgeable (3); 12. Nice job (2); 13. Nice presentation; 14. Slides were difficult to read; 15. Very thorough; 16. Well organized  |
|  | Colleen Teevan, PharmD, BCPS, BCCCP, FCCM; colleen.teevan@hhchealth.org                           |                        |   |                                      |  | 1. Clear/Concise; 2. Easy to follow; 3. Good/Very good/Great/Excellent (8); 4. Good/Very good/Great/Excellent presentation (2); 5. Good/Very good/Great/Excellent speaker (6); 6. Good/Very good/Great/Excellent job (3); 7. Great information; 8. Informative (8); 9. Interesting (2); 10. Knowledgeable (5); 11. Provided relevant information; 12. Thorough; 13. Very nice job; 14. Well organized; 15. Well structured  |

**Pharmacy Technicians**

| Date and Activity Topic  | Speaker(s)  | Total # of Registrants | Total # of Participants receiving CE credit | # of Pharmacy Techs receiving CE credit | Bias, promotion or commercial advertisement (Techs)? | Comments (number of members with same response in parentheses)   |
|--|---|------------------------|---|---|--|--|
| <b>February 11, 2025:</b> Creating a Practical Learning Plan: Effectively Balancing Work and Precepting Duties | Suzanne Higginbotham, PharmD BCACP, CDCES; Suzanne.Higginbotham@osumc.edu                         | 727                    | 543   | 61                                      | NA/None (6)  | 1. Clear/Concise (2); 2. Good/Very good/Great/Excellent speaker (2); 3. Interesting; 4. Informative  |
| <b>April 15, 2025:</b> NIOSH Hazardous Drug Update: Strategies for Your Organization                           | Patricia C. Kienle, RPh, MPA, BCSCP, FASHP; patricia.kienle@cardinal.com                          | 861                    | 669   | 83                                      | NA/None (11)   | 1. Informative (4); 2. Good (2); 3. Good/Very good/Great/Excellent speaker (2); 4. Knowledgeable; 5. Great presentation; 6. Interesting; 7. Well done                                      |
| <b>June 10, 2025:</b> Type 2 Diabetes: Medications, Monitoring, and Management                                 | Hilary Weismantel, PharmD, BCACP, BC-ADM; Hilary.Weismantel@sluhn.org; hilaryweismantel@gmail.com | 685                    | 530   | 66                                      | NA/None (7)  | 1. Good/Very good/Great/Excellent speaker (2); 2. Interesting; 3. Thank you; 4. Clear/Concise (2)  |
| <b>August 7 2025:</b> From Textbook to Tech: Interacting with the Gen Z Learner                                | Megan Adelman Elavsky, BCPS, BCGP, CDCES; ADELMAM2@ccf.org  | 638                    | 478   | 75                                      | NA/None (6)  | 1. Clear/Concise (3); 2. Easy to understand; 3. Thank you; 4. Succinct and engaging; 5. Good/Very good/Great/Excellent (2); 6. Very informative; 7. Excellent presentation; 8. Interesting |
| <b>October 8, 2025:</b> Pharmacy Services Enhancing Patient Outcomes in Transitions of Care                    | Brittany Symonds PharmD, BCACP; Brittany.Symonds@fairview.org                                     | 575                    | 465   | 60                                      | NA/None (4)  | 1. Very informative; 2. Good/Very good/Great/Excellent speaker (2); 3. Thank you; 4. Interesting (2)   |
|  | Shana Steinbeck, PharmD, BCPS; Shana.Steinbeck@fairview.org                                       |                        |   |   |  | 1. Helpful--well done; 2. Good/Very good/Great/Excellent speaker (2); 3. Thank you; 4. Knowledgeable; 5. Interesting   |
| <b>December 2, 2025:</b> Preceptor Development: An AIRXC Collaborative Challenge                               | Frank Szczerba, PharmD, BCPS, BCPPS; frank.szczerba@baystatehealth.org                            | 533                    | 393   | 6                                       | NA/None (1)  | None   |
|  | Colleen Teevan, PharmD, BCPS, BCCCP, FCCM; colleen.teevan@hhchealth.org                           |                        |   |   |  |  |

Premier, Inc.  
Antimicrobial Stewardship Forum Comments Reports  
2025

**Pharmacists**

| Date and Activity Topic  | Speaker(s)  | Total # of Registrants | Total # of Participants receiving CE credit | # of Pharmacists receiving CE credit | Bias, promotion or commercial advertisement? | Comments (number of members with same response in parentheses)  |
|--|---|------------------------|---|--------------------------------------|--|---|
| <b>January 8, 2025:</b> Immunization Communication   | Todd Wolynn MD, MMM; toddwolynn@gmail.com   | 586                    | 443   | 405                                  | NA/None (58)                                 | 1. Clear/Concise (3); 2. Easy to follow; 3. Easy to listen to; 4. Emphasized well on how to communicate with your patient; 5. Engaging (5); 6. Enjoyable; 7. Entertaining; 8. Good/Very good/Great/Excellent (7); 9. Good/Very good/Great/Excellent presentation (6); 10. Excellent review; 11. Good/Very good/Great/Excellent speaker (9); 12. Fantastic; 13. Fantastic job; 14. Good job; 15. Good talk; 16. Good topic; 17. Informative (10); 18. Interesting (4); 19. Job well done; 20. Knowledgeable (3); 21. Nice job; 22. Passionate speaker (2); 23. Professional; 24. Provided current state of social media impacts in public health; 25. Thank you (4); 26. Thorough (2); 27. Wonderful topic   |
| <b>March 11, 2025:</b> IV Push Antimicrobials: Friend or Foe?                                  | Christopher M. Bland, PharmD, FCCP, FIDSA, BCPS; cmbland@uga.edu                          | 823                    | 646   | 561                                  | NA/None (96)                                 | 1. Appreciated the evidence for individual ; 2. Awesome; 3. Clear/Concise (8); 4. Competent; 5. Easy to follow (3); 6. Easy to understand (5); 7. Engaging (3); 8. Good/Very good/Great/Excellent (10); 9. Good pace; 10. Good/Very good/Great/Excellent presentation (22); 11. Good/Very good/Great/Excellent speaker (23); 12. Excellent references; 13. Fantastic speaker; 14. Good/Very good/Great/Excellent job (6); 15. Great content; 16. Informative (14); 17. Interesting (8); 18. Keep up the good work; 19. Knowledgeable (18); 20. Professional; 21. Relevant information; 22. Shared real-world experiences; 23. Speaker communicated his points nicely; 24. Thank you (5); 25. Thorough; 26. Useful topic; 27. Very enlightening; 28. Very organized (3); 29. Very well done; 30. Well versed; 31. Wonderful presentation |
| <b>May 15, 2025:</b> Urinary Infection Updates: Name the Problem Clearly, Manage it Right      | W. Justin Moore, PharmD, BCPS, BCIDP; william.moore@nm.org                                | 756                    | 574   | 502                                  | NA/None (81)                                 | 1. Clear/Concise (6); 2. Easy to follow (2); 3. Engaging; 4. Good/Very good/Great/Excellent (11); 5. Good/Very good/Great/Excellent presentation (20); 6. Good/Very good/Great/Excellent speaker (10); 7. Excellent job; 8. Excellent pace; 9. Great content and delivery; 10. Great job (2); 11. Helpful information; 12. I will save the slides; 13. Incorporation of site-specific guidance was helpful; 14. Informative (16); 15. Interesting (4); 16. Knowledgeable (13); 17. Pleasant, effective communication; 18. Professional (2); 19. Scenarios were a helpful tool; 20. Thank you (5); 21. Thorough (5); 22. Very well done; 23. Well structured; 24. Very well versed; 25. Well organized; 26. Wonderful presentation   |
| <b>July 2, 2025:</b> Outpatient Parenteral Antimicrobial Therapy (OPAT) News to Infuse in 2025 | Monica Mahoney, PharmD, BCPS, BCIDP, FCCP, FIDSA, FIDP, FMSHP; mmahoney@bidmc.harvard.edu | 709                    | 541   | 449                                  | NA/None (68)                                 | 1. Awesome; 2. Clear/Concise (2); 3. Communicated well; 4. Confident/Confident delivery (2); 5. Cool stuff; 6. Detailed (2); 7. Engaging; 8. Good/Very good/Great/Excellent (8); 9. Good/Very good/Great/Excellent presentation (9); 10. Good/Very good/Great/Excellent speaker (12); 11. Excellent job (as always!); 12. Good pace; 13. Good real-world examples; 14. Great job; 15. Informative (11); 16. Interesting (3); 17. Knowledgeable (11); 18. Nice job; 19. OK; 20. Practical advice; 21. Provided a fresh perspective and realistic, tangible methods; 22. Relevant topic (2); 23. Thank you; 24. Very organized; 25. Very thorough; 26. Well prepared  |
| <b>September 4, 2025:</b> New Antimicrobials in Practice: Can We Keep Pace?                    | Ramy Elshaboury, PharmD, BCPS, BCIDP; RELSHABOURY@mgh.harvard.edu                         | 689                    | 484   | 419                                  | NA/None (68)                                 | 1. Another great presentation; 2. Easy to follow; 3. Easy to listen to; 4. Engaging; 5. Good/Very good/Great/Excellent (9); 6. Excellent pace; 7. Good/Very good/Great/Excellent presentation (6); 8. Good/Very good/Great/Excellent speaker (7); 9. Good/Great job (4); 10. Good review; 11. Informative (12); 12. Insightful; 13. Interesting (3); 14. Knowledgeable (11); 15. Phenomenal job; 16. Constructive; 17. Thank you; 18. Thorough (2); 19. Very organized material; 20. Well done; 21. Well prepared   |
| <b>November 12, 2025:</b> Intra-Abdominal Infections Updates (Working title)                   | David W. Kubiak, PharmD, BCPS, BCIDP, FIDSA; dwkubiak@bwh.harvard.edu                     | 646                    | 485   | 417                                  | NA/None (57)                                 | 1. Clear/Concise (3); 2. Difficult to understand; 3. Easy to understand (3); 4. Engaging; 5. Enjoyed this topic; 6. Enthusiastic; 7. Good/Very good/Great/Excellent presentation (13); 8. Good/Very good/Great/Excellent speaker (9); 9. Good (3); 10. Hard to understand at times (2); 11. Inaudible (2); 12. Informative (12); 13. Interesting; 14. Knowledgeable (14); 15. Organized (2); 16. Challenging questions; 17. Well structured slides; 18. Spoke too fast (11); 19.. Thank you (2); 20. Thorough (3); 21. Useful content   |

**Pharmacy Technicians**

| Date and Activity Topic  | Speaker(s)  | Total # of Registrants | Total # of Participants receiving CE credit | # of Pharmacy Techs receiving CE credit | Bias, promotion or commercial advertisement? | Comments (number of members with same response in parentheses)  |
|--|---|------------------------|---|---|--|---|
| <b>January 8, 2025:</b> Immunization Communication   | Todd Wolynn MD, MMM; toddwolynn@gmail.com   | 586                    | 443   | 38                                      | NA/None (4)                                  | 1. Interesting (2); 2. Informative; 3. Very good; 4. Good/Very good/Great/Excellent speaker (3); 5. Screenshots in handout didn't contain content being discussed   |
| <b>March 11, 2025:</b> IV Push Antimicrobials: Friend or Foe?                                  | Christopher M. Bland, PharmD, FCCP, FIDSA, BCPS; cmbland@uga.edu                          | 823                    | 646   | 85                                      | NA/None (11)                                 | 1. Very easy to listen to and understand; 2. Thank you; 3. Excellent information; 4. Very good breakdown of information; 5. Very knowledgeable; 6. Good/Very good/Great/Excellent speaker (2); 7. Good/Very good/Great/Excellent (2); 8. Interesting; 9. Great presentation |
| <b>May 15, 2025:</b> Urinary Infection Updates: Name the Problem Clearly, Manage it Right      | W. Justin Moore, PharmD, BCPS, BCIDP; william.moore@nm.org                                | 756                    | 574   | 72                                      | NA/None (8)                                  | 1. Eloquent speaker; 2. Useful information outline; 3. Good; 4. Excellent speaker; 5. Informative; 6. Interesting; 7. Thank you   |
| <b>July 2, 2025:</b> Outpatient Parenteral Antimicrobial Therapy (OPAT) News to Infuse in 2025 | Monica Mahoney, PharmD, BCPS, BCIDP, FCCP, FIDSA, FIDP, FMSHP; mmahoney@bidmc.harvard.edu | 709                    | 541   | 92                                      | NA/None (10)                                 | 1. Easy to "digest;" 2. Knowledgeable; 3. Easy to understand; 4. Clear/Concise (2); 5. Excellent speaker; 6. Interesting; 7. Thank you; 8. Great topic  |
| <b>September 4, 2025:</b> New Antimicrobials in Practice: Can We Keep Pace?                    | Ramy Elshaboury, PharmD, BCPS, BCIDP; RELSHABOURY@mgh.harvard.edu                         | 689                    | 484   | 65                                      | NA/None (9)                                  | 1. Yes (2); 2. Excellent speaker; 3. Clear/Concise; 4. Interesting; 5. Informative; 6. Thank you; 7. Very good presentation   |
| <b>November 12, 2025:</b> Intra-Abdominal Infections Updates (Working title)                   | David W. Kubiak, PharmD, BCPS, BCIDP, FIDSA; dwkubiak@bwh.harvard.edu                     | 646                    | 485   | 68                                      | NA/None (6)                                  | 1. Interesting (2); 2. Thank you; 3. Difficult to understand; 4. Good/Very good/Great/Excellent speaker (2); 5. Clear/Concise   |

Premier, Inc.  
Home-Study CE Comments Report - Pharmacists  
2025

| Date and Activity Topic  | Speaker(s)  | Credit Hrs | Total # of Registrants | Total # of Participants receiving CE credit | # of Pharmacists receiving CE credit | Bias, promotion or commercial advertisement? | Objectives that were <u>not</u> met   | Comments (number of members with same response in parentheses)  |
|--|---|------------|------------------------|---|--------------------------------------|--|---------------------------------------|---|
| <b>2022 Home-Study CE:</b> Addressing Pharmacy White-bagging at the State Level: How Providers can Engage to Impact Change               | Ken Komorny, PharmD, BCPS; kenneth.komorny@moffitt.org  | 1.0        | 219                    | 169   | 109                                  | NA/None (24)                                 | NA/None (16); Objectives were met (3) | 1. Informative; 2. Honest, real-world examples; 3. Great presentation; 4. Good/Great job (4); 5. Easy to follow and understand; 6. Great (2); 7. Helpful 8. Eye opening   |
| <b>2022 Home-Study CE:</b> At Your Disposal: Safe and Compliant Pharmaceutical Waste   | Bryan C. McCarthy, Jr., PharmD, MS, MJ, FASHP; BMCCarthy@Lifespan.org   | 1.0        | 326                    | 240   | 134                                  | NA/None (20)                                 | NA/None (12)                          | 1. Useful information (2); 2. Thank you; 3. Excellent; 4. Great work; 5. Knowledgeable; 6. Clear/Concise (3); 7. Nice job; 8. Informative (2); 9. Good job (2); 10. Great speaker; 11. Very interesting; 12. Easy to listen to  |
| <b>2022 Home-Study CE:</b> Best Practices for Controlled Substance Diversion Prevention  | Amisha Arya, PharmD, BCSCP; amisha.arya@nyulangone.org  | 1.0        | 183                    | 144   | 87                                   | NA/None (37)                                 | NA/None (30); Objectives met (3)      | 1. Helpful (2); 2. Well done; 3. Good examples and charts (2); 4. Informative(4); 5. Easy to follow (2); 6. Good/Very good/Great/Excellent (5); 7. Engaging; 8. Effective speaker; 9. Knowledgeable (4); 10. Insightful (2); 11. Clear/Concise (2); 12. Thank you; 13. Good/Great job (3); 14. Organized  |
| <b>2022 Home-Study CE:</b> Best Practices Utilizing Diabetes Technology Through Transitions of Care                                      | Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP; dianamisaacs@gmail.com                                      | 1.0        | 341                    | 237   | 128                                  | NA/None (14)                                 | NA/None (8)                           | 1. Knowledgeable; 2. Well presented; 3. Great presentation; 4. Very organized and informative; 5. Fabulous speaker; 6. Nice/Good job (2)  |
| <b>2022 Home-Study CE:</b> CMS Conditions of Participation: Integration into Accreditation Standards                                     | Patricia C. Kienle, RPh, MPA, BCSCP, FASHP; Patricia.Kienle@cardinalhealth.com  | 1.0        | 113                    | 75  | 44                                   | NA/None (12)                                 | NA/None (6)                           | 1. Thank you (4); 2. Well presented; 3. Interesting; 4. Excellent; 5. Great presentation; 6. Informative; 7. Good job   |
| <b>2022 Home-Study CE:</b> Establishment and Impact of Clinical Pharmacy Services in an Accountable Care Organization in a Health System | Genevieve Kumapley, PharmD, BCOP; gkumapley@holyname.org  | 1.0        | 98                     | 87  | 45                                   | NA/None (7)                                  | NA/None (6)                           | 1. Very good; 2. Thank you; 3. Great presentation; Good/Great job (3)   |
| <b>2022 Home-Study CE:</b> Implementation of a System-wide Remote Patient Monitoring Program: Increasing Access with Success             | Cathleen Mathew, PharmD, CDE, AE-C; cathleen.mathew@mountsinai.org<br>Ruchi Tiwari, PharmD, MS; ruchi.tiwari@mountsinai.org | 1.0        | 108                    | 74  | 39                                   | NA/None (15)                                 | NA/None (6)                           | 1. Great presentation; 2. Nice job; 3. Good/Great job (2)<br>1. Wealth of information; 2. Clear and precise   |
| <b>2022 Home-Study CE:</b> Improving Nephrotoxin Stewardship by Utilization of Clinical Surveillance                                     | Sandra Kane-Gill, PharmD, MSc, FCCM, FCCP; kane-gill@pitt.edu   | 1.0        | 113                    | 55  | 35                                   | NA/None (9)                                  | NA/None (4)                           | 1. Interesting; 2. Well done; 3. Informative (2); 4. Organized  |
| <b>2022 Home-Study CE:</b> Managing Acute Pain in Opioid Use Disorder  | Lee Kral, PharmD, BCPS, CPE; lee-kral@uiowa.edu   | 1.0        | 222                    | 132   | 89                                   | NA/None (13)                                 | NA/None (4)                           | 1. Good/Very good/Great/Excellent speaker (2); 2. Awesome; 3. Thank you; 4. Knowledgeable; 5. Easy to understand; 6. Fantastic; 7. Clear/Concise; 8. Excellent presentation; 9. Informative; 10 Engaging  |
| <b>2022 Home-Study CE:</b> Medication Safety and Regulatory Compliance in Ambulatory Surgery Centers                                     | Victor Alves, PharmD, BCGP, FASCP; mailto.valves@octariusrx.com   | 1.0        | 77                     | 66  | 33                                   | NA/None (17)                                 | NA/None (9)                           | 1. Informative; 2. Good; 3. Engaging; 4. Very helpful; 5. Knowledgeable; 6. Good job; 7. Thank you (3)  |
| <b>2022 Home-Study CE:</b> Pharmacy Law and Ethics   | Keith Yoshizuka, PharmD, MBA, JD, FCSHP; kyoshizu@touro.edu   | 1.0        | 142                    | 90  | 57                                   | NA/None (26)                                 | NA/None (14)                          | 1. Good (2); 2. Useful cases (3); 3. Engaging (2); 4. Informative; 5. Thank you (2); 6. Nice job; 7. Clear/Concise; 8. Well presented; 9. Good job; 10. Excellent speaker; 11. Practical application of a potentially nebulous topic; 12. Wonderful course  |
| <b>2022 Home-Study CE:</b> Strategies to Enhance and Expand Your Antimicrobial Stewardship Program                                       | Yi Guo, PharmD, BCIDP, yiguo@montefiore.org   | 1.0        | 149                    | 133   | 70                                   | NA/None (10)                                 | NA/None (4)                           | 1. Well presented; 2. Informative; 3. Good; 4. Provided practical evidence-based information articulately; 5. Decimal point error on Slide 14 (number of FTE per 100 beds); 6. Very nicely done; 7. Good/Very good/Great/Excellent job (2)  |
| <b>2022 Home-Study CE:</b> Successful Management of Formulary Decisions – Controlling Costs Without Compromising Outcomes                | Pavel Goriacko, PharmD, MPH, BCPS; pgoriack@montefiore.org<br>Janelle Duran, PharmD, BCPS; janelle.duran@commonspirit.org   | 1.0        | 96                     | 87  | 46                                   | NA/None (20)                                 | NA/None (11); Objectives were met (5) | 1. Great/Excellent job (3); 2. Good (2); 3. Great/Excellent presentation (2); 4. Valuable information; 5. Informative; 6. Helpful; 7. Organized and clear on topic<br>1. Great/Excellent presentation (2); 2. Good/Great job (3); 3. Good; 4. Very comprehensive; 5. Great information; 6. Informative (2); 7. Easy to follow and nice delivery; 8. Helpful |
| <b>2022 Home-Study CE:</b> The Use of SGLT2 Inhibitors for Heart Failure Management  | Judy Cheng, PharmD, MPH, FCCP, BCPS, RPh; judy.cheng@mcphs.edu  | 1.0        | 410                    | 315   | 227                                  | NA/None (25)                                 | NA/None (8); Objectives were met (1)  | 1. Enthusiastic; 2. Very well presented; great balance of information; 3. Clear/Concise (3); 4. Succinct and helpful; 5. Very effective speaker; Very knowledgeable and caring; 6. Excellent presentation; 7. Fantastic job; 8. Great; 9. Informative; 10. Well organized; 11. Excellent speaker (2)  |
| <b>2023 Home-Study CE:</b> 2023 Accreditation Update   | Patricia C. Kienle, RPh, MPA, FASHP; Patricia.Kienle@cardinalhealth.com   | 1.0        | 207                    | 160   | 89                                   | NA/None (15)                                 | NA/None (5); Objectives were met (2)  | 1. Love [speaker]; 2. Great work; 3. Informative; 4. Clear/Concise; 5. Succinct speaker/presentation (2); 6. Insightful; 7. Great presentation; 8. Knowledgeable; 9. Great organization; 10. Great speaker; 11. Assessment questions and handout material could have been more synchronized   |
| <b>2023 Home-Study CE:</b> A Joint Commission Primer: It's No Pain at All, When You Follow the Standards                                 | Genevieve Kumapley, PharmD, BCOP; gkumapley@holyname.org  | 1.0        | 179                    | 151   | 85                                   | NA/None (17)                                 | NA/None (4); Objectives were met (5)  | 1. Excellent (2); 2. Very good speaker; 3. Thorough; excellent presentation-- thanks; 4. Organized; easy to understand; 5. Nice job; 6. Great work; 7. Informative; 8. Knowledgeable (2); 9. Clean/concise (2)  |
| <b>2023 Home-Study CE:</b> Managing Drug Shortages with a Medication Safety Perspective  | Kathy Ghomeshi, PharmD, MBA, BCPS, CPPS; kg-rx@ghomeshi.com   | 1.0        | 272                    | 239   | 141                                  | NA/None (27)                                 | NA/None (13); Objectives were met (2) | 1. Well organized (2); 2. Excellent presentation; 3. Useful content/references (2); 4. Med error rates for benchmarking would have been useful; 5. Great work; 6. Nice job; 7. Knowledgeable (4); 8. Informative; 9. Thank you; 10. Engaging (2); 11. Very practical  |
| <b>2023 Home-Study CE:</b> Optimizing Use of Novel Agents to Treat Multidrug-resistant Gram-negative Infections                          | Ryan K. Shields, PharmD, MS; shieldsrk@upmc.edu   | 1.0        | 189                    | 144   | 87                                   | NA/None (14)                                 | NA/None (5); Objectives were met (1)  | 1. Great visuals for future reference; 2. Excellent (2); 3. Very comprehensive; 4. Easy to follow (2); 5. Clear/Concise (2); 6. Excellent speaker; 7. Great job/work (2); 8. Outstanding; 9. Very helpful information   |
| <b>2023 Home-Study CE:</b> Perioperative Antimicrobial Stewardship and Pharmacy's Role   | Sara Jordan Hyland, PharmD, BCCCP; Sara.Jordan@ohiohealth.com   | 1.0        | 233                    | 148   | 77                                   | NA/None (9)                                  | NA/None (3)                           | 1. Good/Very good/Great/Excellent (3); 2. Great presentation (2); 3. Great speaker (2); 4. Thank you (2); 5. Informative (3); 6. Really liked topic; 7. Clear/Concise; 8. Knowledgeable and effective speaker; 9. Wonderful CE; 10. Good job  |

Premier, Inc.  
Home-Study CE Comments Report - Pharmacists  
2025

| Date and Activity Topic  | Speaker(s)  | Credit Hrs | Total # of Registrants | Total # of Participants receiving CE credit | # of Pharmacists receiving CE credit | Bias, promotion or commercial advertisement? | Objectives that were <u>not</u> met   | Comments (number of members with same response in parentheses)   |
|--|---|------------|------------------------|---|--------------------------------------|--|---------------------------------------|--|
| 2023 Home-Study CE: Thrombolytics for Acute Ischemic Stroke: Have We Found the Right (Tenecte)Phase in Therapy?  | Karen Berger, PharmD, FCCM, BCPS, BCCCP; karenberger7@gmail.com   | 1.0        | 299                    | 213   | 141                                  | NA/None (67)                                 | NA/None (43); Objectives were met (2) | 1. Awesome; 2. Clear/Concise; 3. Easy to understand (3); 4. Effective presentation (2); 5. Enjoyable; 6. Good/Very good/Great/Excellent presentation (9); 7. Good/Very good/Great/Excellent speaker (5); 8. Good/Very good/Great/Excellent (7); 9. Excellent summarization of the trials; 10. Great summary of literature; 11. Informative (6); 12. Knowledgeable (5); 13. Really liked the commentary/call-out on non-disabling minor stroke 2019 guideline change; 14. Thank you; 15. Very comprehensive presentation; 16. Very nice; 17. Very nice job; 18. Very organized (4); 19. Very well done (2); 20. Very well presented; 21. Detailed; 22. Easy to follow |
| 2023 Home-Study CE: Updates in HIV Treatment and Prevention (HIV/AIDS)   | Melanie Berry, PharmD, BCACP; mberry2@bidmc.harvard.edu   | 1.0        | 206                    | 143   | 83                                   | NA/None (10)                                 | NA/None (7); Objectives were          | 1. Excellent; 2. Good/Very good/Great/Excellent presentation (2); 3. An abbreviation key would have been helpful; 4. Well organized  |
| 2024 Home-Study CE: Reversal of Direct Factor-Xa Inhibitors, An Evidence Update  | Michael P. Gulseth, Pharm. D., BCPS, FMSHP, FASHP; michael.gulseth@sanfordhealth.org                                      | 1.0        | 221                    | 120   | 85                                   | NA/None (11)                                 | NA/None (2)                           | 1. Knowledgeable; 2. Good/Very good/Great/Excellent presentation (3); 3. Informative; 4. Great job summarizing data; 5. Nice review of current literature; 6. Thank you; 7. Great job; 8. Questions not clearly answered, specifically case report   |
| 2024 Home-Study CE: 2024-2025 Influenza Virus and Vaccine Update   | Premier Staff   | 1.0        | 244                    | 167   | 101                                  | NA/None (11)                                 | NA/None (2)                           | Thank you (5)  |
| 2025 Home-Study CE: 2025-2026 Influenza Virus and Vaccine Update   | Premier Staff   | 1.0        | 133                    | 87  | 59                                   | NA/None (9)                                  | NA/None (2)                           | None   |
| 2025 Home-Study CE: 340B Program - Looking Forward to 2025 After Another Tumultuous Year   | Jason B. Reddish; Jason.Reddish@PowersLaw.com   | 1.0        | 96                     | 51  | 29                                   | NA/None (2)                                  | NA/None (1)                           | Nice job; interesting topic  |
| 2025 Home-Study CE: Buprenorphine in the Management of Opioid Use Disorder (OUD): Updates on Role in Therapy, Accessibility, and Novel Dosing Strategies | Michael Biglow, PharmD, BCPS, BCPP; mbiglow@pfs.org   | 1.0        | 157                    | 97  | 71                                   | NA/None (5)                                  | NA/None (2)                           | 1. Informative; 2. Nice job; 3. Excellent presentation   |
| 2025 Home-Study CE: Don't Get Lost in the Alphabet Soup: Overview of Emerging Cancer Immune Therapies  | Genevieve Kumapley, PharmD, BCOP; gkumapley@holyname.org  | 1.0        | 43                     | 36  | 21                                   | NA/None (3)                                  | None                                  | None   |
| 2025 Home-Study CE: How It's Made: 503B Product Ingredients and Sterilization Methods  | Kevin N. Hansen, PharmD, MS, BCSCP; kevin_hansen@premierinc.com   | 1.0        | 74                     | 57  | 39                                   | NA/None (5)                                  | NA/None (1)                           | 1. Good/Very good/Great/Excellent presentation (2); 2. Thorough; 3. Nice job; 4. Easy to follow; 5. Knowledgeable (2); 6. Informative  |
| 2025 Home-Study CE: Immunization Communication   | Todd Wolynn MD, MMM; toddwolynn@gmail.com   | 1.0        | 61                     | 41  | 25                                   | None   | None                                  | Interesting; thank you   |
| 2025 Home-Study CE: Incorporating Anti-Amyloid-B (AB) Monoclonal Antibody Therapies into Alzheimer's Disease Management                                  | Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP; marketa.marvanova@pacificu.edu   | 1.0        | 56                     | 32  | 16                                   | NA/None (2)                                  | None                                  | 1. Great speaker; 2. Fine  |
| 2025 Home-Study CE: IV Push Antimicrobials: Friend or Foe?   | Christopher M. Bland, PharmD; FCCP, FIDSA, BCPS:  | 1.0        | 112                    | 79  | 51                                   | NA/None (6)                                  | NA/None (4)                           | 1. Absolutely fantastic; 2. Informative (2); 3. Knowledgeable; 4. Clear/Concise; 5. Amazing; 6. Engaging; 7. Fine  |
| 2025 Home-Study CE: Multiple Sclerosis: Overview and Advances in Treatment   | Mitra Habibi, PharmD; mhabib1@uic.edu   | 1.0        | 51                     | 40  | 21                                   | NA/None (3)                                  | NA/None (1)                           | 1. Nice job; 2. Good presentation, but audio was poor; 3. Great  |
| 2025 Home-Study CE: NIOSH Hazardous Drug Update: Strategies for Your Organization  | Patricia C. Kienle, RPh, MPA, BCSCP, FASHP; patricia.kienle@cardinalhealth.com  | 1.0        | 85                     | 52  | 39                                   | NA/None (5)                                  | NA/None (2)                           | 1. Nice presentation; 2. Good presentation; 3. [Amazingly] knowledgeable and outstanding instructor; thank you   |
| 2025 Home-Study CE: Pharmacy Considerations for the Optimal Utilization of T-Cell Engaging Bispecific Antibodies for Hematologic Malignancies            | Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP; donald.moore1@atriumhealth.org  | 1.0        | 30                     | 21  | 9                                    | None   | None                                  | None   |
| 2025 Home-Study CE: Protecting Our Little Ones! Reducing Medication Errors in Neonates and Pediatrics  | Judith Scala, PharmD, BCPPS; JScala@saintpetersuh.com   | 1.0        | 233                    | 171   | 115                                  | NA/None (12)                                 | NA/None (6)                           | 1. Target audience was not [inpatient] hospital pharmacists; 2. Good information; 3. Well done (2); 4. Good speaker (2); 5. Knowledgeable (2); 6. Nice presentation (2); 7. Engaging; 8. Wonderful slides  |
| 2025 Home-Study CE: Sterile Compounding: Compliance Tips for Inspections and Surveys   | Patricia C. Kienle, RPh, MPA, BCSCP, FASHP; patricia.kienle@cardinalhealth.com  | 1.0        | 102                    | 27  | 21                                   | None   | None                                  | 1. Good job (2); 2. Excellent speaker  |
| 2025 Home-Study CE: The Future is Now: The Impact of Artificial Intelligence on Medication Use Safety  | Steven Smoke, PharmD, BCIDP; steven.smoke@rwjbh.org<br>Daniel T. Abazia, PharmD, BCPS, CPPS; dabazia@pharmacy.rutgers.edu | 1.0        | 177                    | 132   | 88                                   | NA/None (11)                                 | NA/None (3)                           | 1. Great information; 2. Knowledgeable (2); 3. Good; 4. great topic; 5. Excellent applications to practice; 6. Informative; 7. Thank you<br>1. Great information; 2. Knowledgeable (3); 3. Good presentation; 4. Nice job; 5. Engaging; 6. Interesting; 7. Informative   |

Premier, Inc.  
Home-Study CE Comments Report - Pharmacy Technicians  
2025

| Date and Activity Topic   | Speaker(s)   | Credit Hrs | Total # of Registrants | Total # of Participants receiving CE credit | # of Pharmacy Techs receiving CE credit | Bias, promotion or commercial advertisement? | Objectives that were <u>not</u> met   | Comments (number of members with same response in parentheses)  |
|---|--|------------|------------------------|---|---|--|---------------------------------------|---|
| <b>2022 Homestudy CE:</b> Addressing Pharmacy White-bagging at the State Level: How Providers can Engage to Impact Change               | Ken Komorny, PharmD, BCPS; kenneth.komorny@moffitt.org                                 | 1.0        | 219                    | 169   | 60                                      | NA/None (27)                                 | NA/None (15)                          | 1. Helpful; 2. Good/Great (4); 3. Thanks; 4. Well done; 5. Informative (4); 6. Great presentation (2); 7. Great job; 8. Enjoyed this CE; 9. Great speaker; 10. I liked it |
| <b>2022 Homestudy CE:</b> At Your Disposal: Safe and Compliant Pharmaceutical Waste   | Bryan C. McCarthy, Jr., PharmD, MS, MJ, FASHP; BMcCarthy@Lifespan.org                  | 1.0        | 326                    | 240   | 106                                     | NA/None (28)                                 | NA/None (19)                          | 1. Good (5); 2. Thank you (2); 3. Clear/Concise (3); 4. Informative (2); 5. Very knowledgeable; 6. Great speaker  |
| <b>2022 Homestudy CE:</b> Best Practices for Controlled Substance Diversion Prevention  | Amisha Arya, PharmD, BCSCP; amisha.arya@nyulangone.org                                 | 1.0        | 183                    | 144   | 57                                      | NA/None (21)                                 | NA/None (21)                          | 1. Great job (2); 2. Great presentation; 3. Clear/Concise; 4. Well done; 5. Informative   |
| <b>2022 Homestudy CE:</b> Best Practices Utilizing Diabetes Technology Through Transitions of Care                                      | Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP; dianamisaacs@gmail.com | 1.0        | 341                    | 237   | 109                                     | NA/None (13)                                 | NA/None (6)                           | 1. Very good; 2. Very informative; 3. Amazing; 4. Passionate; 5. Engaging; 6. Knowledgeable (2)   |
| <b>2022 Homestudy CE:</b> CMS Conditions of Participation: Integration into Accreditation Standards                                     | Patricia C. Kienle, RPh, MPA, BCSCP, FASHP; Patricia.Kienle@cardinalhealth.com         | 1.0        | 113                    | 75  | 31                                      | NA/None (7)                                  | NA/None (5)                           | 1. Interesting  |
| <b>2022 Homestudy CE:</b> Establishment and Impact of Clinical Pharmacy Services in an Accountable Care Organization in a Health System | Genevieve Kumapley, PharmD, BCOP; gkumapley@holyname.org                               | 1.0        | 98                     | 87  | 42                                      | NA/None (10)                                 | NA/None (8)                           | 1. Great information; 2. Nice job   |
| <b>2022 Homestudy CE:</b> Implementation of a system-wide remote patient monitoring program: increasing access with success             | Cathleen Mathew, PharmD, CDE, AE-C; cathleen.mathew@mountsinai.org                     | 1.0        | 108                    | 74  | 35                                      | NA/None (8)                                  | NA/None (6)                           | 1. Difficult to hear the presentation; 2. Great job   |
|   | Ruchi Tiwari, PharmD, MS; ruchi.tiwari@mountsinai.org                                  |            |                        |   |   |  |                                       | 1. Clear and precise  |
| <b>2022 Homestudy CE:</b> Improving Nephrotoxin Stewardship by Utilization of Clinical Surveillance                                     | Sandra Kane-Gill, PharmD, MSc, FCCM, FCCP; kane-gill@pitt.edu                          | 1.0        | 113                    | 55  | 20                                      | NA/None (8)                                  | NA/None (7)                           | None  |
| <b>2022 Homestudy CE:</b> Managing Acute Pain in Opioid Use Disorder  | Lee Kral, PharmD, BCPS, CPE; lee-kral@uiowa.edu  | 1.0        | 222                    | 132   | 43                                      | NA/None (9)                                  | NA/None (4)                           | 1 Good (2) 2. Informative   |
| <b>2022 Homestudy CE:</b> Medication Safety and Regulatory Compliance in Ambulatory Surgery Centers                                     | Victor Alves, PharmD, BCGP, FASCP; mailto:valves@octariusrx.com                        | 1.0        | 77                     | 66  | 33                                      | NA/None (16)                                 | NA/None (10); Objectives were met (1) | 1. Good speaker; 2. Clear/Concise; 3. I learned something new   |
| <b>2022 Homestudy CE:</b> Pharmacy Law and Ethics   | Keith Yoshizuka, PharmD, MBA, JD, FCSHP; kyoshizu@touro.edu                            | 1.0        | 142                    | 90  | 33                                      | NA/None (10)                                 | NA/None (6)                           | 1. Very good speaker; 2. Clear/Concise; 3. Good; 4. Good job  |
| <b>2022 Homestudy CE:</b> Strategies to Enhance and Expand Your Antimicrobial Stewardship Program                                       | Yi Guo, PharmD, BCIDP, yiguo@montefiore.org  | 1.0        | 149                    | 133   | 63                                      | NA/None (14)                                 | NA/None (11)                          | 1. Very informative; 2. Great job; 3. Good; 4. Enjoyed the CE   |
| <b>2022 Homestudy CE:</b> Successful Management of Formulary Decisions – Controlling Costs Without Compromising Outcomes                | Pavel Goriacko, PharmD, MPH, BCPS; pgoriack@montefiore.org                             | 1.0        | 96                     | 87  | 41                                      | NA/None (16)                                 | NA/None (14)                          | 1. Good; 2. Great information   |
|   | Janelle Duran, PharmD, BCPS; janelle.duran@commonspirit.org                            |            |                        |   |   |  |                                       | 1. Good   |
| <b>2022 Homestudy CE:</b> The Use of SGLT2 Inhibitors for Heart Failure Management  | Judy Cheng, PharmD, MPH, FCCP, BCPS, RPh; judy.cheng@mcphs.edu                         | 1.0        | 410                    | 315   | 88                                      | NA/None (7)                                  | NA/None (3)                           | 1. Knowledgeable (2); 2. Spoke too quickly; 3. Clear/Concise  |
| <b>2023 Home-Study CE:</b> 2023 Accreditation Update  | Patricia C. Kienle, RPh, MPA, FASHP; Patricia.Kienle@cardinalhealth.com                | 1.0        | 207                    | 160   | 71                                      | NA/None (13)                                 | NA/None (4)                           | 1. Knowledgeable; 2. Clear/Concise (2); 3. Informative (2); 4. Good speaker; 5. Thank you   |
| <b>2023 Home-Study CE:</b> A Joint Commission Primer: It's No Pain at All, When You Follow the Standards                                | Genevieve Kumapley, PharmD, BCOP; gkumapley@holyname.org                               | 1.0        | 179                    | 151   | 66                                      | NA/None (11)                                 | NA/None (10)                          | 1. Good (2); 2. Informative; 3. Clear/Concise   |
| <b>2023 Home-Study CE:</b> Managing Drug Shortages with a Medication Safety Perspective   | Kathy Ghomeshi, PharmD, MBA, BCPS, CPPS; kg-rx@ghomeshi.com                            | 1.0        | 272                    | 239   | 98                                      | NA/None (26)                                 | NA/None (19); Objectives were met (1) | 1. Good/Very good/Great/Excellent (5); 2. Thank you; 3. Informative (2); 4. Great presentation; 5. Easy to follow   |
| <b>2023 Homestudy CE:</b> Optimizing Use of Novel Agents to Treat Multidrug-resistant Gram-negative Infections                          | Ryan K. Shields, PharmD, MS; shieldsrk@upmc.edu  | 1.0        | 189                    | 144   | 57                                      | NA/None (17)                                 | NA/None (12)                          | 1. Good (3)   |
| <b>2023 Home-Study CE:</b> Perioperative Antimicrobial Stewardship and Pharmacy's Role  | Sara Jordan Hyland, PharmD, BCCCP; Sara.Jordan@ohiohealth.com                          | 1.0        | 233                    | 148   | 71                                      | NA/None (7)                                  | NA/None (4)                           | 1. Good/Very good/Great/Excellent (4); 2. Informative   |
| <b>2023 Home-Study CE:</b> Thrombolytics for Acute Ischemic Stroke: Have We Found the Right (Tenecte)Phase in Therapy?                  | Karen Berger, PharmD, FCCM, BCPS, BCCCP; karenberger7@gmail.com                        | 1.0        | 299                    | 213   | 72                                      | NA/None (14)                                 | NA/None (13); Objectives were met (1) | 1. Good presentation; 2. Wonderful; 3. Great job; 4. Good; 5. Well prepared; clear/concise; 6. Keep up the good work  |
| <b>2023 Home-Study CE:</b> Updates in HIV Treatment and Prevention (HIV/AIDS)   | Melanie Berry, PharmD, BCACP; mberry2@bidmc.harvard.edu                                | 1.0        | 206                    | 143   | 60                                      | NA/None (17)                                 | NA/None (12)                          | 1. Useful information; 2.Knowledgeable; 3. Clear/Concise; 4. Very good presentation; 5. Informative; 6. Very comprehensive  |
| <b>2024 Home-Study CE:</b> Reversal of Direct Factor-Xa Inhibitors, An Evidence Update  | Michael P. Gulseth, Pharm. D., BCPS, FMSHP, FASHP; michael.gulseth@sanfordhealth.org   | 1.0        | 221                    | 120   | 35                                      | NA/None (5)                                  | NA/None (4)                           | None  |
| <b>2024 Home-Study CE:</b> 2024-2025 Influenza Virus and Vaccine Update   | Premier Staff  | 1.0        | 244                    | 167   | 66                                      | NA/None (9)                                  | NA/None (4)                           | None  |

Premier, Inc.  
Home-Study CE Comments Report - Pharmacy Technicians  
2025

| Date and Activity Topic   | Speaker(s)  | Credit Hrs | Total # of Registrants | Total # of Participants receiving CE credit | # of Pharmacy Techs receiving CE credit | Bias, promotion or commercial advertisement? | Objectives that were <u>not</u> met | Comments (number of members with same response in parentheses)  |
|---|---|------------|------------------------|---|---|--|-------------------------------------|---|
| <b>2025 Home-Study CE:</b> 2025-2026 Influenza Virus and Vaccine Update   | Premier Staff   | 1.0        | 133                    | 87  | 28                                      | NA/None (3)                                  | NA/None (2)                         | Maybe gather a broader array of professionals as authors  |
| <b>2025 Home-Study CE:</b> 340B Program - Looking Forward to 2025 After Another Tumultuous Year   | Jason B. Reddish; Jason.Reddish@PowersLaw.com   | 1.0        | 96                     | 51  | 22                                      | NA/None (1)                                  | NA/None (1)                         | 1. Too technical; 2. Difficult to follow  |
| <b>2025 Home-Study CE:</b> Buprenorphine in the Management of Opioid Use Disorder (OUD): Updates on Role in Therapy, Accessibility, and Novel Dosing Strategies | Michael Biglow, PharmD, BCPS, BCPP; mbiglow@phs.org   | 1.0        | 157                    | 97  | 26                                      | NA/None (1)                                  | NA/None (1)                         | Interesting and helpful information   |
| <b>2025 Home-Study CE:</b> Don't Get Lost in the Alphabet Soup: Overview of Emerging Cancer Immune Therapies  | Genevieve Kumapley, PharmD, BCOP; gkumapley@holyname.org  | 1.0        | 43                     | 36  | 15                                      | NA/None (2)                                  | NA/None (2)                         | None  |
| <b>2025 Home-Study CE:</b> How It's Made: 503B Product Ingredients and Sterilization Methods  | Kevin N. Hansen, PharmD, MS, BCSCP; kevin_hansen@premierinc.com   | 1.0        | 74                     | 57  | 18                                      | NA/None (2)                                  | NA/None (1)                         | None  |
| <b>2025 Home-Study CE:</b> Immunization Communication   | Todd Wolynn MD, MMM; toddwolynn@gmail.com   | 1.0        | 61                     | 41  | 16                                      | NA/None (2)                                  | NA/None (2)                         | None  |
| <b>2025 Home-Study CE:</b> Incorporating Anti-Amyloid-B (AB) Monoclonal Antibody Therapies into Alzheimer's Disease Management                                  | Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP; marketa.marvanova@pacificu.edu   | 1.0        | 56                     | 32  | 16                                      | NA/None (1)                                  | None                                | None  |
| <b>2025 Home-Study CE:</b> IV Push Antimicrobials: Friend or Foe?   | Christopher M. Bland, PharmD; FCCP, FIDSA, BCPS:  | 1.0        | 112                    | 79  | 28                                      | NA/None (2)                                  | NA/None (3)                         | Great speaker   |
| <b>2025 Home-Study CE:</b> Multiple Sclerosis: Overview and Advances in Treatment   | Mitra Habibi, PharmD; mhabib1@uic.edu   | 1.0        | 51                     | 40  | 19                                      | NA/None (3)                                  | NA/None (2)                         | None  |
| <b>2025 Home-Study CE:</b> NIOSH Hazardous Drug Update: Strategies for Your Organization  | Patricia C. Kienle, RPh, MPA, BCSCP, FASHP; patricia.kienle@cardinalhealth.com  | 1.0        | 85                     | 52  | 13                                      | NA/None (2)                                  | NA/None (2)                         | None  |
| <b>2025 Home-Study CE:</b> Pharmacy Considerations for the Optimal Utilization of T-Cell Engaging Bispecific Antibodies for Hematologic Malignancies            | Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP; donald.moore1@atriumhealth.org  | 1.0        | 30                     | 21  | 12                                      | NA/None (2)                                  | NA/None (2)                         | None  |
| <b>2025 Home-Study CE:</b> Protecting Our Little Ones! Reducing Medication Errors in Neonates and Pediatrics  | Judith Scala, PharmD, BCPPS; JScala@saintpetersuh.com   | 1.0        | 233                    | 171   | 56                                      | NA/None (6)                                  | NA/None (3)                         | Useful and easy-to-follow information   |
| <b>2025 Home-Study CE:</b> Sterile Compounding: Compliance Tips for Inspections and Surveys   | Patricia C. Kienle, RPh, MPA, BCSCP, FASHP; patricia.kienle@cardinalhealth.com  | 1.0        | 102                    | 27  | 6                                       | None   | None                                | None  |
| <b>2025 Home-Study CE:</b> The Future is Now: The Impact of Artificial Intelligence on Medication Use Safety  | Steven Smoke, PharmD, BCIDP; steven.smoke@rwjbh.org<br>Daniel T. Abazia, PharmD, BCPS, CPPS; dabazia@pharmacy.rutgers.edu | 1.0        | 177                    | 132   | 44                                      | NA/None (7)                                  | NA/None (3)                         | 1. Clear/Concise; 2. Informative; 3. Good presentation<br>1. Good job; 2. Good presentation; 3. Informative |

Premier, Inc.  
Breakthroughs CE Comments Report  
2025

**Pharmacists**

| Date and Activity Topic  | Speaker(s)   | Total # of Registrants | Total # of Participants receiving CE credit | Total # of Pharmacists receiving CE credit | Bias, promotion or commercial advertisement? | Comments (number of members with same response in parentheses) |
|--|--|------------------------|---|--|--|--|
| July 16, 2025: Central Pharmacy: Pros and Challenges                                 | Thomas Matanich, MBA, PMP;<br>Thomas.Matanich@bhsi.com   | 21                     | 21  | 20   | NA/None (2)                                  | 1. Informative (2); 2. Thorough; 3. Engaging                   |
|  | Jordan M. Propst, PharmD, RPh;<br>Jordan.Propst@bhsi.com   |                        |   |  |  | 1. Informative (2); 2. Engaging                                |
| July 16, 2025: Creative Strategies to Optimize Pharmacy Drug Supply Chain Resiliency | Samantha Bailey PharmD, BCPS;<br>samantha.a.bailey@adventhealth.com  | 23                     | 23  | 22   | NA/None (2)                                  | 1. Good speaker; 2. Informative and effective                  |
| July 17, 2025: Now That It's Broke... How Do I Fix It? Lessons from Hurricane Helene | Karen Hancock, RPh; Karen_Hancock@bshsi.org  | 12                     | 11  | 10   | NA/None (1)                                  | 1. Very well done; 2. Great job                                |
| July 17, 2025: Preceptor Development: an AIRXC Collaborative Challenge               | Frank Szczerba, PharmD, BCPS, BCPPS;<br>Frank.Szczerba@baystatehealth.org  | 8                      | 8   | 8  | NA/None (2)                                  | Good (2)   |
|  | Gladys Dabaja, PharmD; gdabaja1@hfhs.org   |                        |   |  |  |  |
|  | Colleen Teevan, PharmD, BCPS, BCCCP, FCCM;<br>Colleen.Teevan@hhchealth.org                                       |                        |   |  |  |  |
| July 17, 2025: Why Pharmacy Needs to Take a Lead in PBM Change                       | Leslie Hurst, PharmD, BCACP; Leslie.Hurst@bhsi.com<br>Nilesh Desai, BS, RPh, MBA, CPPS;<br>Nilesh.Desai@bhsi.com | 10                     | 10  | 9  | None   | None   |

**Pharmacy Technicians**

| Date and Activity Topic  | Speaker(s)   | Total # of Registrants | Total # of Participants receiving CE credit | Total # of Pharmacy Technicians receiving CE credit | Bias, promotion or commercial advertisement? | Comments (number of members with same response in parentheses) |
|--|--|------------------------|---|---|--|--|
| July 16, 2025: Central Pharmacy: Pros and Challenges                                 | Thomas Matanich, MBA, PMP;<br>Thomas.Matanich@bhsi.com   | 21                     | 21  | 1   | None   | Great information; very helpful                                |
|  | Jordan M. Propst, PharmD, RPh;<br>Jordan.Propst@bhsi.com   |                        |   |   |  | Detailed information   |
| July 16, 2025: Creative Strategies to Optimize Pharmacy Drug Supply Chain Resiliency | Samantha Bailey PharmD, BCPS;<br>samantha.a.bailey@adventhealth.com  | 23                     | 23  | 1   | None   | Very good presentation   |
| July 17, 2025: Now That It's Broke... How Do I Fix It? Lessons from Hurricane Helene | Karen Hancock, RPh; Karen_Hancock@bshsi.org  | 12                     | 11  | 1   | None   | None   |
| July 17, 2025: Preceptor Development: an AIRXC Collaborative Challenge               | Frank Szczerba, PharmD, BCPS, BCPPS;<br>Frank.Szczerba@baystatehealth.org  | 8                      | 8   | -   | -  | -  |
|  | Gladys Dabaja, PharmD; gdabaja1@hfhs.org   |                        |   |   |  |  |
|  | Colleen Teevan, PharmD, BCPS, BCCCP, FCCM;<br>Colleen.Teevan@hhchealth.org                                       |                        |   |   |  |  |
| July 17, 2025: Why Pharmacy Needs to Take a Lead in PBM Change                       | Leslie Hurst, PharmD, BCACP; Leslie.Hurst@bhsi.com<br>Nilesh Desai, BS, RPh, MBA, CPPS;<br>Nilesh.Desai@bhsi.com | 10                     | 10  | 1   | None   | None   |

Premier, Inc.  
Atlantic Health CE Comments Report  
2025

| Date and Activity Topic  | Speaker(s)  | Total # of Registrants | Total # of Participants receiving CE credit | # of Pharmacy Technicians receiving CE credit | Bias, promotion or commercial advertisement? | Comments (number of members with same response in parentheses)   |
|--|---|------------------------|---|---|--|--|
| <b>June 5, 2025:</b> Clot Busters: Thrombolytics for Acute Ischemic Stroke   | Angela Bonetti, PharmD;<br>Angela.Bonetti@atlanticealth.org   | 40                     | 38  | 0   | NA/None (9)                                  | 1. Good/Very good/Great/Excellent job (3); 2. Good/Very good/Great/Excellent presentation (2); 3. Clear/Concise (3); 4. Well organized; 5. Informative (2); 6. Relevant to hospital practice; 7. Easy to follow; 8. Great speaker; 9. Very knowledgeable |
| <b>June 9, 2025:</b> The Pharmacist's Role in Acute Respiratory Distress Syndrome: Beyond the Ventilator                                 | Alayna Sedgwick, PharmD;<br>Alayna.Sedgwick@atlanticealth.org | 30                     | 25  | 0   | NA/None (2)                                  | 1. Well explained; 2. information was basic; 3. Great job; 4. Clear/Concise  |
| <b>June 11, 2025:</b> <i>Helicobacter Pylori</i> : Infection and Treatment – 2024 American College of Gastroenterology Guideline Updates | Alexis Rotondo, PharmD;<br>Alexis.Rotondo@atlanticealth.org   | 24                     | 24  | 0   | NA/None (4)                                  | 1. Good/Very good/Great/Excellent presentation (2); 2. Great job; 3. Great speaker; 4. Clear/Concise; 5. Informative; 6. Slides looked good; 7. Hard to hear at times  |
| <b>June 17, 2025:</b> Blinatumomab Utilization in Pediatric Acute Lymphoblastic Leukemia   | Marta Galagoza, PharmD;<br>Marta.Galagoza@atlanticealth.org   | 28                     | 26  | 0   | NA/None (3)                                  | 1. Well done; 2. Informative (3); 3. Professional; 4. Good/Very good/Great/Excellent job (2); 5. I learned a lot; 6. Well organized; 6. Great pace; 7. Clear/Concise; 8. Great presentation; 9. Confident speaker; 10. Great learning experience         |
| <b>June 18, 2025:</b> Rethinking Withdrawal: Clinical Utilization of Phenobarbital in Alcohol Withdrawal Syndrome                        | Jolie Schojbert, PharmD;<br>Jolie.Schojbert@atlanticealth.org | 34                     | 32  | 0   | NA/None (4)                                  | 1. Great job (2); 2. I learned a lot; 3. Informative; 4. Excellent presentation (2); 5. Awesome job; 6. Well organized (3); 7. Detailed; 8. Clear/Concise  |

Premier, Inc.  
Pharmacy Executives Conference, Capstone, Yankee Alliance and Premier Member Meeting CE Comments Reports  
2025

**Premier Executives Conference CEs**

| Date and Activity Topic   | Speaker(s)                                 | Total # of Registrants | Total # of Participants receiving CE credit | # of Pharmacy Technicians receiving CE credit | Bias, promotion or commercial advertisement? | Comments (number of members with same response in parentheses)            |
|---|--|------------------------|---|---|--|---|
| October 28, 2025: Navigating 340B in Maryland in Financial Headwinds          | Jason Reddish; Jason.Reddish@PowersLaw.com | 6                      | 6   | -   | NA/None (2)                                  | 1. Very knowledgeable; 2. Good/Very good/Great/Excellent presentation (2) |
| November 6, 2025: The Intersection of Pharmacy & Policy: Washington DC Update | Soumi Saha; soumi_saha@premierinc.com      | 18                     | 18  | -   | NA/None (3)                                  | Timely information; great job   |

**Capstone CEs**

| Date and Activity Topic   | Speaker(s)  | Total # of Registrants | Total # of Participants receiving CE credit | # of Pharmacy Technicians receiving CE credit | Bias, promotion or commercial advertisement? | Comments (number of members with same response in parentheses) |
|---|---|------------------------|---|---|--|--|
| October 21, 2025: The 2025 Update on Biosimilars  | Liya Davydov, PharmD, BCPS, BCGP; Liya_Davydov@premierinc.com | 4                      | 4   | 1   | None   | None   |
| October 22, 2025: Specialty, Oncology, and ID Drugs: What is in the Pipeline? - The 2025 Update | Liya Davydov, PharmD, BCPS, BCGP; Liya_Davydov@premierinc.com | 4                      | 3   | 0   | NA/None (1)                                  | 1. Great presentation and timely; 2. Great job                 |
| October 23, 2025: Why Pharmacy Needs to Take a lead in a PBM Change                             | Nilesh Desai BS, RPh, MBA, CPPS; Nilesh.Desai@bhsi.com        | 3                      | 1   | 0   | NA/None (1)                                  | Great presentation and timely                                  |

**Yankee Alliance CEs**

| Date and Activity Topic   | Speaker(s)  | Total # of Registrants | Total # of Participants Receiving CE credit | # of Pharmacists Receiving CE credit | # of Pharmacy Technicians Receiving CE credit | Bias, promotion or commercial advertisement? | Comments (number of members with same response in parentheses)    |
|---|---|------------------------|---|--------------------------------------|---|--|---|
| October 27, 2025: The Intersection of Pharmacy & Policy: Washington DC Update | Soumi Saha, PharmD, JD; soumi_saha@premierinc.com   | 9                      | 6   | 6                                    | -   | NA/None (1)                                  | 1. Very knowledgeable, great speaker; 2. Always great; 3. Amazing |
| October 28, 2025: Central Pharmacy: Pros and Challenges                       | Thomas Matanich, MBA, PMP; Thomas.Matanich@bhsi.com | 5                      | 5   | 5                                    | -   | NA/None (1)                                  | Mr. Matanich was great  |

**Premier Member Meeting CEs**

| Date and Activity Topic  | Speaker(s)  | Total # of Registrants | Total # of Participants receiving CE credit | # of Pharmacy Technicians receiving CE credit | Bias, promotion or commercial advertisement? | Comments (number of members with same response in parentheses)   |
|--|---|------------------------|---|---|--|--|
| December 7, 2025: Visionary leadership in a time of volatility in pharmacy (Working title) | Sandy Salverson, PharmD, MBA, BCPS, CPEL; sandy.salverson@osfhealthcare.org | 40                     | 30  | -   | NA/None (10)                                 | 1. Informative (2); 2. Timely information; 3. Clear/Concise (2); 4. Knowledgeable (3); 5. Engaging; 6. Great speaker; 7. Great presentation  |
| December 7, 2025: Home and Alternative Site Infusion Payer Landscape                       | Bill Noyes; bill.noyes@nhia.org   | 35                     | 26  | 1   | NA/None (7)                                  | 1. Good/Very good/Great/Excellent speaker (3); 2. Informative; 3. Provided real-world experiences and approaches; 4. Wonderful speaker; 5. Engaging and thorough; 6. Knowledgeable; 7. Enjoyable; 8. Thank you |

**Premier, Inc.**  
**2025 Overall CE Activity Rating Averages**

| Date and Activity Topic  | Speaker(s)  | Total # of Registrants | Total # of CE Credit Recipients | Overall CE Activity Rating Averages |              |
|--|---|------------------------|---------------------------------|-------------------------------------|--------------|
| <b>CE Activity</b>   |   |                        |                                 |                                     |              |
| <b>TeleCEs</b>   |   |                        |                                 |                                     |              |
|  |   |                        |                                 | <b>Pharmacist</b>                   | <b>Techs</b> |
| <b>January 23, 2025:</b> 340B Program – Looking Forward to 2025 After Another Tumultuous Year  | Jason B. Reddish; Jason.Reddish@PowersLaw.com   | 845                    | 622                             | 4.41                                | 4.37         |
| <b>February 25, 2025:</b> Clean Data and Polished Compliance: Leveraging AI Diversion Software to Optimize Alerts and Improve Controlled Substance Processes | Bethanie Gamble, PharmD; Bethanie.Gamble@prismahealth.org   | 689                    | 526                             | 4.37                                | 4.45         |
| <b>March 27, 2025:</b> Don't Get Lost in the Alphabet Soup: Overview of Emerging Cancer Immune Therapies   | Genevieve Kumapley, PharmD, BCOP; gkumapley@holyname.org  | 714                    | 542                             | 4.41                                | 4.41         |
| <b>April 23, 2025:</b> Health Equity in Practice: Addressing Bias and Social Drivers for Better Patient Outcomes   | Sally A. Arif, PharmD, BCCP; sarif@midwestern.edu   | 697                    | 520                             | 4.40                                | 4.39         |
| <b>May 29, 2025:</b> How It's Made: 503B Product Ingredients and Sterilization Methods   | Kevin N. Hansen, PharmD, MS, BCSCP; kevin_hansen@premierinc.com                                   | 753                    | 557                             | 4.47                                | 4.41         |
| <b>June 17, 2025:</b> Incorporating Anti-Amyloid-β (Aβ) Monoclonal Antibody Therapies into Alzheimer's Disease Management                                    | Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP; marketa.marvanova@pacificu.edu                 | 686                    | 517                             | 4.44                                | 4.43         |
| <b>July 23, 2025:</b> Specialty, Oncology, and ID Drugs: What is in the Pipeline? - The 2025 Update  | Liya Davydov, PharmD, BCPS, BCGP; Liya_Davydov@premierinc.com                                     | 474                    | 361                             | 4.36                                | 4.35         |
| <b>August 13, 2025:</b> Biosimilars -The 2025 Update   | Liya Davydov, PharmD, BCPS, BCGP; Liya_Davydov@premierinc.com                                     | 698                    | 664                             | 4.38                                | 4.43         |
| <b>September 18, 2025:</b> Leading with Intelligence: Embracing AI to Advance Pharmacy   | Rebecca A. Taylor, PharmD, MBA, BCPS, FASHP; taylorra4@upmc.edu                                   | 641                    | 503                             | 4.34                                | 4.43         |
| <b>October 23, 2025:</b> Stopping the Bleed in 2025: An Anticoagulation Reversal and Hemostasis Update   | Michael Gulseth, PharmD, BCPS, FMSHP, FASHP; michael.gulseth@sanfordhealth.org                    | 662                    | 508                             | 4.41                                | 4.34         |
| <b>November 19, 2025:</b> From Guidelines to Bedside: Evolving HIV Care in Hospitalized Patients   | Shannon Balcombe, PharmD, BCPS, AAHVP; sbalcombe@health.ucsd.edu                                  | 621                    | 471                             | 4.45                                | 4.36         |
| <b>December 17, 2025:</b> Human Trafficking from a Pharmacy Perspective (Working title)  | Anne Haring, PharmD; Anne_Haring@pba.edu; annieferri@yahoo.com                                    | 544                    | 448                             | 4.45                                | 4.38         |
|  | Yasmin Grace, BS, PharmD; Yasmin_Grace@pba.edu  |                        |                                 |                                     |              |
| <b>ASFs</b>  |   |                        |                                 |                                     |              |
| <b>January 8, 2025:</b> Immunization Communication   | Todd Wolynn MD, MMM; toddwolynn@gmail.com   | 586                    | 443                             | 4.40                                | 4.30         |
| <b>March 11, 2025:</b> IV Push Antimicrobials: Friend or Foe?  | Christopher M. Bland, PharmD, FCCP, FIDSA, BCPS; cmbland@uga.edu                                  | 823                    | 646                             | 4.50                                | 4.41         |
| <b>May 15, 2025:</b> Urinary Infection Updates: Name the Problem Clearly, Manage it Right  | W. Justin Moore, PharmD, BCPS, BCIDP; william.moore@nm.org  | 756                    | 574                             | 4.50                                | 4.31         |
| <b>July 2, 2025:</b> Outpatient Parenteral Antimicrobial Therapy (OPAT) News to Infuse in 2025   | Monica Mahoney, PharmD, BCPS, BCIDP, FCCP, FIDSA, FIDP, FMSHP; mmahoney@bidmc.harvard.edu         | 709                    | 541                             | 4.45                                | 4.41         |
| <b>September 4, 2025:</b> New Antimicrobials in Practice: Can We Keep Pace?  | Ramy Elshaboury, PharmD, BCPS, BCIDP; RELSHABOURY@mgh.harvard.edu                                 | 689                    | 484                             | 4.45                                | 4.36         |
| <b>November 12, 2025:</b> Intra-Abdominal Infections Updates (Working title)   | David W. Kubiak, PharmD, BCPS, BCIDP, FIDSA; dwkubiak@bwh.harvard.edu                             | 646                    | 485                             | 4.42                                | 4.31         |
| <b>PPFs</b>  |   |                        |                                 |                                     |              |
| <b>February 11, 2025:</b> Creating a Practical Learning Plan: Effectively Balancing Work and Precepting Duties   | Suzanne Higginbotham, PharmD BCACP, CDCES; Suzanne.Higginbotham@osumc.edu                         | 727                    | 543                             | 4.46                                | 4.37         |
| <b>April 15, 2025:</b> NIOSH Hazardous Drug Update: Strategies for Your Organization   | Patricia C. Kienle, RPh, MPA, BCSCP, FASHP; patricia.kienle@cardinal.com                          | 861                    | 669                             | 4.49                                | 4.42         |
| <b>June 10, 2025:</b> Type 2 Diabetes: Medications, Monitoring, and Management   | Hilary Weismantel, PharmD, BCACP, BC-ADM; Hilary.Weismantel@sluhn.org; hilaryweismantel@gmail.com | 685                    | 530                             | 4.48                                | 4.46         |
| <b>August 7 2025:</b> From Textbook to Tech: Interacting with the Gen Z Learner  | Megan Adelman Elavsky, BCPS, BCGP, CDCES; ADELMAM2@ccf.org  | 638                    | 478                             | 4.40                                | 4.34         |
| <b>October 8, 2025:</b> Pharmacy Services Enhancing Patient Outcomes in Transitions of Care  | Brittany Symonds PharmD, BCACP; Brittany.Symonds@fairview.org                                     | 575                    | 465                             | 4.40                                | 4.38         |
|  | Shana Steinbeck, PharmD, BCPS; Shana.Steinbeck@fairview.org                                       |                        |                                 |                                     |              |
| <b>December 2, 2025:</b> Preceptor Development: An AIRXC Collaborative Challenge   | Frank Szczerba, PharmD, BCPS, BCPPS; frank.szczerba@baystatehealth.org                            | 533                    | 393                             | 4.43                                | 4.33         |
|  | Colleen Teevan, PharmD, BCPS, BCCCP, FCCM; colleen.teevan@hhchealth.org                           |                        |                                 |                                     |              |
| <b>AllSpire CEs</b>  |   |                        |                                 |                                     |              |
| <b>June 5, 2025:</b> Clot Busters: Thrombolytics for Acute Ischemic Stroke   | Angela Bonetti, PharmD; Angela.Bonetti@atlanticealth.org  | 40                     | 38                              | 4.88                                | -            |
| <b>June 9, 2025:</b> The Pharmacist's Role in Acute Respiratory Distress Syndrome: Beyond the Ventilator   | Alayna Sedgwick, PharmD; Alayna.Sedgwick@atlanticealth.org  | 30                     | 25                              | 4.87                                | -            |
| <b>June 11, 2025:</b> <i>Helicobacter Pylori</i> : Infection and Treatment – 2024 American College of Gastroenterology Guideline Updates                     | Alexis Rotondo, PharmD; Alexis.Rotondo@atlanticealth.org  | 24                     | 24                              | 4.73                                | -            |
| <b>June 17, 2025:</b> Blinatumomab Utilization in Pediatric Acute Lymphoblastic Leukemia   | Marta Galagoza, PharmD; Marta.Galagoza@atlanticealth.org  | 28                     | 26                              | 4.79                                | -            |
| <b>June 18, 2025:</b> Rethinking Withdrawal: Clinical Utilization of Phenobarbital in Alcohol Withdrawal Syndrome  | Jolie Schojbert, PharmD; Jolie.Schojbert@atlanticealth.org  | 34                     | 32                              | 4.81                                | -            |

**Premier, Inc.**  
**2025 Overall CE Activity Rating Averages**

| Date and Activity Topic   | Speaker(s)  | Total # of Registrants | Total # of CE Credit Recipients | Overall CE Activity Rating Averages |      |
|---|---|------------------------|---------------------------------|-------------------------------------|------|
| <b>CE Activity</b>  |   |                        |                                 |                                     |      |
| <b>Breakthroughs CEs</b>  |   |                        |                                 |                                     |      |
| <b>July 16, 2025:</b> Central Pharmacy: Pros and Challenges   | Thomas Matanich, MBA, PMP; Thomas.Matanich@bhsi.com<br>Jordan M. Propst, PharmD, RPh; Jordan.Propst@bhsi.com  | 21                     | 21                              | 4.82                                | 4.00 |
| <b>July 16, 2025:</b> Creative Strategies to Optimize Pharmacy Drug Supply Chain Resiliency   | Samantha Bailey PharmD, BCPS; samantha.a.bailey@adventhealth.com  | 23                     | 23                              | 4.73                                | 4.00 |
| <b>July 17, 2025:</b> Now That It's Broke... How Do I Fix It? Lessons from Hurricane Helene   | Karen Hancock, RPh; Karen_Hancock@bshsi.org   | 12                     | 11                              | 5.00                                | 5.00 |
| <b>July 17, 2025:</b> Preceptor Development: an AIRXC Collaborative Challenge   | Frank Szczerba, PharmD, BCPS, BCPPS; Frank.Szczerba@baystatehealth.org<br>Gladys Dabaja, PharmD; gdabaja1@hfhs.org<br>Colleen Teevan, PharmD, BCPS, BCCCP, FCCM; Colleen.Teevan@hhchealth.org | 8                      | 8                               | 4.70                                | -    |
| <b>July 17, 2025:</b> Why Pharmacy Needs to Take a Lead in PBM Change   | Leslie Hurst, PharmD, BCACP; Leslie.Hurst@bhsi.com<br>Nilesh Desai, BS, RPh, MBA, CPPS; Nilesh.Desai@bhsi.com   | 10                     | 10                              | 4.89                                | 5.00 |
| <b>Home Study CEs</b>   |   |                        |                                 |                                     |      |
| <b>2022 Homestudy CE:</b> Addressing Pharmacy White-bagging at the State Level: How Providers can Engage to Impact Change               | Ken Komorny, PharmD, BCPS; kenneth.komorny@moffitt.org  | 219                    | 109                             | 4.64                                | 4.37 |
| <b>2022 Homestudy CE:</b> At Your Disposal: Safe and Compliant Pharmaceutical Waste   | Bryan C. McCarthy, Jr., PharmD, MS, MJ, FASHP; BMcCarthy@Lifespan.org   | 326                    | 240                             | 4.59                                | 4.39 |
| <b>2022 Homestudy CE:</b> Best Practices for Controlled Substance Diversion Prevention  | Amisha Arya, PharmD, BCSCP; amisha.arya@nyulangone.org  | 183                    | 144                             | 4.58                                | 4.43 |
| <b>2022 Homestudy CE:</b> Best Practices Utilizing Diabetes Technology Through Transitions of Care                                      | Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP; dianamisaacs@gmail.com  | 341                    | 237                             | 4.61                                | 4.48 |
| <b>2022 Homestudy CE:</b> CMS Conditions of Participation: Integration into Accreditation Standards                                     | Patricia C. Kienle, RPh, MPA, BCSCP, FASHP; Patricia.Kienle@cardinalhealth.com  | 113                    | 75                              | 4.62                                | 4.47 |
| <b>2022 Homestudy CE:</b> Establishment and Impact of Clinical Pharmacy Services in an Accountable Care Organization in a Health System | Genevieve Kumapley, PharmD, BCOP; gkumapley@holyname.org  | 98                     | 87                              | 4.61                                | 4.49 |
| <b>2022 Homestudy CE:</b> Implementation of a System-Wide Remote Patient Monitoring Program: Increasing Access with Success             | Cathleen Mathew, PharmD, CDE, AE-C; cathleen.mathew@mountsinai.org<br>Ruchi Tiwari, PharmD, MS; ruchi.tiwari@mountsinai.org   | 108                    | 74                              | 4.60                                | 4.48 |
| <b>2022 Homestudy CE:</b> Improving Nephrotoxin Stewardship by Utilization of Clinical Surveillance                                     | Sandra Kane-Gill, PharmD, MSc, FCCM, FCCP; kane-gill@pitt.edu   | 113                    | 55                              | 4.62                                | 4.45 |
| <b>2022 Homestudy CE:</b> Managing Acute Pain in Opioid Use Disorder  | Lee Kral, PharmD, BCPS, CPE; lee-kral@uiowa.edu   | 222                    | 132                             | 4.61                                | 4.52 |
| <b>2022 Homestudy CE:</b> Medication Safety and Regulatory Compliance in Ambulatory Surgery Centers                                     | Victor Alves, PharmD, BCGP, FASCP; mailto:valves@octariusrx.com   | 443                    | 361                             | 4.56                                | 4.44 |
| <b>2022 Homestudy CE:</b> Pharmacy Law and Ethics   | Keith Yoshizuka, PharmD, MBA, JD, FCSHP; kyoshizu@touro.edu   | 142                    | 90                              | 4.63                                | 4.48 |
| <b>2022 Homestudy CE:</b> Strategies to Enhance and Expand Your Antimicrobial Stewardship Program                                       | Yi Guo, PharmD, BCIDP, yiguo@montefiore.org   | 149                    | 133                             | 4.66                                | 4.37 |
| <b>2022 Homestudy CE:</b> Successful Management of Formulary Decisions – Controlling Costs Without Compromising Outcomes                | Pavel Goriacko, PharmD, MPH, BCPS; pgoriack@montefiore.org<br>Janelle Duran, PharmD, BCPS; janelle.duran@commonspirit.org   | 96                     | 87                              | 4.61                                | 4.52 |
| <b>2022 Homestudy CE:</b> The Use of SGLT2 Inhibitors for Heart Failure Management  | Judy Cheng, PharmD, MPH, FCCP, BCPS, RPh; judy.cheng@mcphs.edu  | 410                    | 315                             | 4.63                                | 4.38 |
| <b>2023 Home-Study CE:</b> 2023 Accreditation Update  | Patricia C. Kienle, RPh, MPA, FASHP; Patricia.Kienle@cardinalhealth.com   | 207                    | 160                             | 4.54                                | 4.35 |
| <b>2023 Home-Study CE:</b> A Joint Commission Primer: It's No Pain at All, When You Follow the Standards                                | Genevieve Kumapley, PharmD, BCOP; gkumapley@holyname.org  | 179                    | 151                             | 4.58                                | 4.37 |
| <b>2023 Home-Study CE:</b> Managing Drug Shortages with a Medication Safety Perspective   | Kathy Ghomeshi, PharmD, MBA, BCPS, CPPS; kg-rx@ghomeshi.com   | 272                    | 239                             | 4.62                                | 4.45 |
| <b>2023 Homestudy CE:</b> Optimizing Use of Novel Agents to Treat Multidrug-resistant Gram-negative Infections                          | Ryan K. Shields, PharmD, MS; shieldsrk@upmc.edu   | 189                    | 144                             | 4.67                                | 4.40 |
| <b>2023 Home-Study CE:</b> Perioperative Antimicrobial Stewardship and Pharmacy's Role  | Sara Jordan Hyland, PharmD, BCCCP; Sara.Jordan@ohiohealth.com   | 233                    | 148                             | 4.66                                | 4.37 |
| <b>2023 Home-Study CE:</b> Thrombolytics for Acute Ischemic Stroke: Have We Found the Right (Tenece)Plase in Therapy?                   | Karen Berger, PharmD, FCCM, BCPS, BCCCP; karenberger7@gmail.com   | 299                    | 213                             | 4.66                                | 4.48 |
| <b>2023 Home-Study CE:</b> Updates in HIV Treatment and Prevention (HIV/AIDS)   | Melanie Berry, PharmD, BCACP; mberry2@bidmc.harvard.edu   | 206                    | 143                             | 4.60                                | 4.39 |
| <b>2024 Home-Study CE:</b> Reversal of Direct Factor-Xa Inhibitors, An Evidence Update  | Michael P. Gulseth, Pharm. D., BCPS, FMSHP, FASHP; michael.gulseth@sanfordhealth.org  | 221                    | 120                             | 4.65                                | 4.28 |
| <b>2024 Home-Study CE:</b> 2024-2025 Influenza Virus and Vaccine Update   | Premier Staff   | 244                    | 167                             | 4.68                                | 4.53 |